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Abstract
Decellularized adipose tissue (DAT) represents a promising adipogenic bioscaffold for
applications in soft tissue augmentation or reconstruction. With the goal of investigating
the role of syngeneic donor adipose-derived stem/stromal cells (ASCs) and host myeloid
cells during in vivo adipose tissue regeneration, transgenic reporter mouse strains were
used to track these cell populations within ASC-seeded and unseeded DAT scaffolds.
Donor ASCs were obtained from dsRed transgenic mice. These cells were shown to
express characteristic cell surface markers, and multilineage differentiation capacity was
confirmed. To facilitate cell tracking, DAT scaffolds were subcutaneously implanted into
MacGreen mice in which myeloid cells express enhanced green fluorescent protein
(EGFP). ASC-seeded DAT scaffolds augmented total cell recruitment as well as
adipogenesis, and influenced EGFP+ myeloid cell infiltration kinetics within the implants.
The donor dsRed+ ASCs were retained within the DAT scaffolds up to 8 weeks postimplantation, and did not contribute directly to the newly formed adipocytes.
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Chapter 1

1

Introduction

1.1 Project motivation and rationale
Subcutaneous adipose tissue (fat) is an integral component of the integumentary system,
functioning to store energy and provide insulation. However, adipose tissue has a limited
capacity for self-renewal; damage can lead to scar tissue formation and contracture, for
example in cases of trauma, lipodystrophies, and oncologic resection [1, 2]. Current
reconstructive and cosmetic procedures for soft tissue augmentation include the use of
dermal fillers and fat grafts; however, these are associated with poor long-term retention,
high costs, and the potential for surgical complications [3]. To address the clinical need
for stable and effective soft tissue replacements, previous work from the Flynn laboratory
has demonstrated that decellularized adipose tissue (DAT) scaffolds represent a
promising tissue-specific platform for the delivery of adipose-derived stem/stromal cells
(ASCs) as an adipose tissue engineering strategy [4, 5]. In particular, subcutaneous
implantation of the DAT into an immunocompetent Wistar rat model demonstrated that
ASC-seeded scaffolds helped to stimulate angiogenesis and host-derived fat formation
[4]. Importantly, the allogeneic donor ASCs were shown to support a pro-regenerative
microenvironment associated with increased expression of the anti-inflammatory
cytokine interleukin (IL)-10, and a shift toward a more constructive M2 macrophage
phenotype [4].
ASCs can secrete a wide array of angiogenic and chemotactic factors, as well as
immunomodulatory cytokines including IL-10, IL-13, hepatocyte growth factor (HGF),
and leukemia inhibitory factor (LIF), depending on the local microenvironment [6].
Supporting that transplanted ASCs may promote regeneration through indirect paracrine
mechanisms by modulating the immune response, in vitro co-culture studies have
confirmed that ASCs can promote the expression of M2 macrophage markers through
contact-independent mechanisms [7-10]. Furthermore, Dong et al. demonstrated that
donor ASCs incorporated into human fat grafts increased the fraction of M2-like
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macrophages and improved implant survival within an athymic mouse model [11]. Other
mesenchymal stem/stromal cell (MSC) populations have also been shown to enhance the
recruitment of monocytes and macrophages through chemotactic factor production [12,
13], indicating another key mechanism through which the ASCs could modulate the
inflammatory response.
The immunomodulatory activity of ASCs is an attractive feature supporting their use in
adipose tissue engineering since macrophages and inflammation have been shown to play
an integral role in fat formation. Using a silicone-encased Matrigel chamber as an
engineering model for neo-adipogenesis, Thomas et al. demonstrated that the addition of
the sterile inflammation agent Zymosan into the chamber significantly augmented fat
formation [14]. Moreover, incorporation of the agent aminoguanidine to attenuate
inflammation was shown to reverse these effects [14]. The same group showed that
adipose tissue regeneration was associated with an initial infiltration of bone marrowderived macrophages thought to be important for recruiting adipocyte precursors
originating from the bone marrow as well as neighbouring tissues [15]. A follow-up study
revealed that macrophages played an integral role in the regenerative process. Local
depletion of macrophages using Clodronate liposomes incorporated into the Matrigel
chamber resulted in a dramatic reduction in angiogenesis and adipogenesis within the
system [16]. Interestingly, a similar role for inflammation has been implicated in the
pathophysiology of obesity. More specifically, the degree of adipose tissue macrophage
infiltration has been correlated to adiposity [17], with macrophages being a significant
source of pro-inflammatory cytokines that contribute to the chronic inflammatory state
associated with this condition [18-20]. Collectively, these findings support a key role for
macrophages in adipogenesis.
The pro-adipogenic DAT scaffolds have been shown to retain features of the complex
adipose tissue extracellular matrix (ECM) [21], and display similar biomechanical
properties to native human fat [22, 23]. As such, the DAT represents a rational cellinstructive delivery vehicle for ASCs in an adipose tissue engineering strategy [4].
Building on a promising foundation of previous in vitro and in vivo data, there is a need
to develop a deeper understanding of regenerative mechanisms mediated by DAT
2

scaffolds and ASCs. As such, the primary goal of the current study was to track and
characterize infiltrating myeloid cells, including macrophages, as well as donor ASCs in
tandem through the use of dual transgenic reporter mouse models. The results of this
work support the rationale for a tissue-specific approach for cell delivery and tissue
engineering, and suggest the need for further investigation of the role of inflammation in
adipose tissue regeneration.

1.2 Hypothesis and specific aims
The hypothesis for this work was that syngeneic donor ASCs will influence myeloid cell
infiltration kinetics, and will enhance cell recruitment and adipogenesis within DAT
scaffolds implanted subcutaneously in mice. To facilitate donor ASC cell tracking,
ASCs were isolated from transgenic Discosoma red fluorescent protein (dsRed) mice
(B6.Cg-Tg(CAG-DsRed*MST)1Nagy/J; C57BL/6J background; Jackson Laboratory,
Bar Harbor, ME) in which all cells express dsRed under the control of the chicken beta
actin promoter coupled with the cytomegalovirus (CMV) immediate early enhancer [24].
DAT scaffolds seeded with dsRed+ ASCs were implanted subcutaneously along with
unseeded controls into MacGreen transgenic reporter mice (B6N.Cg-Tg(Csf1rEGFP)1Hume/J; C57BL/6J background; Jackson Laboratory, Bar Harbor, ME) in which
cells of the myeloid lineage (including macrophages, monocytes and neutrophils) express
enhanced green fluorescent protein (EGFP) under the control of the mouse colony
stimulating factor 1 receptor (Csf1r) promoter [25, 26]. To address the central hypothesis,
the specific aims of this Master’s thesis were:
1) To characterize the cell surface phenotype and multilineage differentiation capacity
(adipogenic, chondrogenic, and osteogenic) of ASCs isolated from the inguinal fat
pad of dsRed mice, and to establish methods for seeding the murine ASCs onto the
DAT scaffolds.
2) To assess total cell infiltration and adipogenesis within ASC-seeded and unseeded
DAT scaffolds implanted subcutaneously into the MacGreen mouse model over 8
weeks.
3) To perform ASC tracking studies to assess donor ASC retention within the implanted
DAT scaffolds.
3

4) To characterize the myeloid cell population infiltrating the DAT implants through
immunohistochemical staining for macrophage markers.
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Chapter 2

2

Literature Review

Sections of this chapter were included in the review article “Robb KP, Shridhar A, Flynn
LE. Decellularized matrices as cell-instructive scaffolds to guide tissue-specific
regeneration. ACS Biomaterials Science & Engineering. Accepted Nov. 13, 2017. DOI:
10.1021/acsbiomaterials.7b00619”

2.1 Adipose tissue engineering
2.1.1

Adipose tissue composition, structure, and function

Adipose tissue is a specialized form of loose connective tissue that functions primarily as
a regulator of energy homeostasis. Fat is distributed within subcutaneous and visceral
depots, including in the epicardial and intramuscular regions, as well as in the bone
marrow [27]. In mammals, adipose tissue exists in two forms: brown adipose tissue
(BAT) and white adipose tissue (WAT) [28]. BAT is predominantly found in neonates
and in hibernating mammals, and functions as a mechanism of heat generation via nonshivering thermogenesis [29]. Brown adipocytes represent a small fraction of adipocytes
in adult humans; however, BAT is thought to play a potential metabolic role in obesity,
as low levels of BAT have been correlated to increased body mass index (BMI) and fat
accumulation in humans and animal models [30, 31]. WAT comprises the majority of
adipose tissue in adults and functions to store energy in the form of triglycerides and
other lipids [32]. In response to energy demands and hormonal stimuli, triglycerides are
hydrolyzed forming free fatty acids and glycerol that are released by adipocytes into the
circulation, allowing subsequent cellular uptake and conversion to energy sources via
downstream biochemical pathways [33]. Given that WAT is a major component of
subcutaneous tissues, it has been of predominant interest in adipose tissue engineering
strategies. In developing these strategies, WAT also represents a convenient source of
both cells and scaffolding material [5, 34, 35], as discussed in detail in Sections 2.2 and
2.3.

5

A wide variety of cell types are found in adipose tissue, with adipocytes representing the
largest proportion [36]. Adipocytes are terminally-differentiated cells specialized to store
and release lipids contained within a lipid droplet, which comprises >90% of the total cell
volume [37]. Other cell types found in adipose tissue include adipose-derived
stem/stromal cells (ASCs; discussed in Section 2.2) as well as more committed preadipocytes that give rise to adipocytes [38]. Adipose tissue is highly vascularized, with
each adipocyte supplied by an extensive capillary network, allowing for uptake and
release of nutrients and waste products [39]. Further, adipose tissue also receives
significant innervation from both sympathetic and parasympathetic inputs that act in
concert to regulate lipid metabolism [40]. Adding to the complexity of this tissue is the
presence of immune cells including macrophages, neutrophils, and lymphocytes, which
are found at low levels within healthy adipose tissue [28]. In the pathophysiology of
obesity, increased levels of adipose tissue macrophages (ATMs) are associated with
adiposity [17], and the pro-inflammatory cytokines released by ATMs are a key
contributor to chronic inflammation in obese patients [18-20].
As mentioned, the main function of WAT is energy storage, but it also provides
mechanical cushioning and insulates the body to prevent heat loss [41]. Moreover, WAT
is an essential endocrine organ, secreting adipose tissue cytokines, known as adipokines,
which are involved in a variety of processes including nutritional control, angiogenesis,
vascular homeostasis, blood pressure control, and inflammation [42, 43]. Of these, leptin
was the first-discovered adipokine recognized for its role in mediating energy balance
and metabolism by regulating appetite [44]. Adiponectin is another well-studied
adipokine known to display pleiotropic actions including regulation of gluconeogenesis,
glucose uptake, and lipid catabolism [45]. In addition, adiponectin displays antiinflammatory functions associated with reduced tumour necrosis-factor-alpha (TNFα)
and interleukin (IL)-6 production in adipose tissue and other tissues, as well as increased
IL-10 secretion [46]. Other known adipokines include plasminogen activator inhibitor-1
(PAI-1) involved in fibrinolysis and regulation of insulin sensitivity [47], and the proangiogenic protein, vascular endothelial growth factor (VEGF) [48].

6

2.1.2

Current strategies for adipose tissue engineering

Adipose tissue has a limited capacity for self-repair; thus, damage or deficits can lead to
scar tissue formation and contracture [1, 2]. A range of conditions are associated with
subcutaneous adipose tissue deficits including congenital defects, lipodystrophies, aging,
trauma, and cancer [49, 50]. Plastic and reconstructive surgeries to treat such
abnormalities are highly prevalent, with 290,000 breast augmentations, 2.6 million soft
tissue filler procedures, and 4.5 million oncologic resections performed in the United
States in 2016 [51]. For small volume deficits, current treatment options include
autologous fat transfer and dermal fillers such as hyaluronic acid-based materials [52,
53]. However, these treatments are associated with poor long-term retention necessitating
regular follow-up treatments, and in the case of fat grafting, there is the potential for oil
cyst formation [53-56]. The preferred treatment option for larger volume deficits involves
autologous tissue transfer of vascularized flaps of skin, fat, and muscle [57] but these
procedures are costly, and have high complication rates, including donor site morbidity
[3].
Synthetic implants have been explored as an alternative treatment for adipose tissue
deficits. These include biocompatible absorbable polymers such as poly(lactic-coglycolic acid) (PLGA), polyglycolic acid (PGA), and polylactic acid (PLA) [2, 58, 59].
Synthetic polymers offer the advantage of controlled tuning of the biomechanical
properties and degradation rate via cross-linking, enabling the design of a material that
matches the mechanical properties of the tissue of interest, as well as the potential for
controlled release of growth factors or cytokines [60]. However, the long-term retention
of synthetic materials in vivo remains a significant hurdle [61, 62], along with issues
related to fibrous encapsulation of the implants which can cause severe pain, as well as
implant migration and rupture [63].
Naturally-derived materials represent an additional avenue of exploration for the
treatment of adipose tissue abnormalities. For example, collagen scaffolds have been
shown to support angiogenesis and adipogenesis in vivo [64, 65]. Bellas et al.
demonstrated that porous silk sponges seeded with lipoaspirate retained their volume
7

over the course of an 18 month study in a subcutaneous nude rat model [66].
Additionally, injectable alginate-based scaffolds have been shown to support
adipogenesis in vitro and in vivo [67, 68]. In the category of naturally-derived materials,
decellularized scaffolds have been investigated with the goal of retaining instructive
extracellular matrix (ECM) components to guide tissue regeneration [3]. Given that this
is a primary focus of this work, ECM-derived scaffolds will be discussed in detail in
Section 2.3.
While ECM-derived scaffolds have shown promise in tissue engineering applications,
there is emerging evidence to support that combination strategies involving the dual use
of cell-instructive scaffolds with stem/progenitor cells may be more effective than either
cells or scaffolds alone [63, 69]. In particular, donor stem/progenitor cells can help to
stimulate regeneration within implanted ECM-derived scaffolds, and can be conveniently
sourced from adult tissues. Stem/progenitor cell sourcing and regenerative mechanisms
are discussed in greater detail below, with an emphasis on the utility of ASCs in adipose
tissue engineering.

2.2 ASCs as a regenerative cell source
Mesenchymal stem/stromal cells (MSCs) are a cell population capable of in vitro clonal
expansion and multipotent differentiation [70, 71]. MSCs are a commonly studied
regenerative cell source first discovered in the adult bone marrow [70, 71]; however,
MSC populations have since been identified and isolated from a variety of other adult
tissues, including adipose tissue and peripheral blood, as well as from the dermis, heart,
and lungs [72-76]. In particular, MSCs sourced from adipose tissue (ASCs) have received
growing interest due to their ease of access through minimally invasive procedures, and
the ability to obtain higher yields of these cells relative to bone marrow-derived MSCs
(bmMSCs) [77]. Immunohistochemical analysis has suggested that in native tissues,
ASCs reside in the perivascular niche adjacent to neighbouring endothelial cells and
pericytes [78]; however, their exact localization remains controversial due to the lack of
unique markers to identify the population [79, 80]. With the aim of standardizing
approaches for ASC characterization, the International Federation for Adipose
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Therapeutics and Science (IFATS) in conjunction with the International Society for
Cellular Therapy (ISCT) have defined ASCs as having the following minimum criteria:
1) ASCs are plastic-adherent cells, 2) ASCs should express a standard cell surface
phenotypic profile (described in more detail below), and 3) ASCs should maintain in
vitro multipotency toward the adipogenic, osteogenic, and chondrogenic lineages [81].

2.2.1

ASC isolation procedures

A variety of methods have been developed for the isolation of ASCs from adipose tissue,
including from lipoaspirate [82-84]. In general, these protocols involve enzymatic
digestion and separation steps via centrifugation to yield the stromal vascular fraction
(SVF), a heterogeneous population of cells consisting of MSCs, pre-adipocytes,
endothelial progenitor cells, fibroblasts, pericytes, circulating blood cells, macrophages,
and smooth muscle cells [85, 86]. The ASC population can then be further purified from
the SVF through selection and expansion of the adherent cell population on tissue culture
plastic. However, this plastic-adherent population remains heterogeneous in terms of cell
morphology (including small rapidly self-renewing cells, spindle-like cells, and large
flattened cells), as well as the presence of variable ratios of uni-, bi-, and tri-potent cells,
progenitors, and more differentiated subpopulations [87-90]. Importantly, the wide array
of ASC isolation procedures and growth conditions can influence the yield, expansion
rates, and differentiation capacity of these cells [91, 92]. Attempts to standardize these
procedures are ongoing in order to improve the consistency and reproducibility of the
therapeutic efficacy of ASCs for clinical applications.
ASCs can be isolated from both visceral and subcutaneous depots in a variety of
anatomical locations, and there is increasing evidence that ASCs sourced from different
locations display functional differences in vitro [93, 94]. For example, a previous study
from our laboratory comparing ASCs isolated from subcutaneous, omental, pericardial,
and thymic remnant depots, showed that levels of osteogenic differentiation were
enhanced in ASCs harvested from the omentum, while adipogenic differentiation was
augmented in ASCs derived from the subcutaneous and pericardial depots [95].
Moreover, ASCs isolated from lipoaspirate sourced from the upper arm and medial thigh
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have been reported to display higher proliferative and differentiation capacities relative to
fat from the trochanteric and superficial or deep abdominal regions [96]. This depotdependency could potentially be exploited in the application of ASCs in cell-based
therapies by extracting specific populations that may be predisposed toward a desired
cellular fate. In addition to the influence of adipose tissue depots, donor health status,
BMI, age, sex, and other factors contribute to donor variability in terms of the yield and
functionality of ASCs [97-100]. However, the influence of these factors is difficult to
study due to their complexity and interdependency, and further work involving largescale studies is required in order to better understand the impact of these different factors
on the therapeutic potential of ASCs.
While the study of human ASCs is important for clinical translation, investigation of
ASCs from other mammalian sources is important for pre-clinical model studies to
develop a deeper understanding of the mechanisms of ASC-mediated tissue regeneration.
In contrast to human ASCs, mouse ASCs have been far less well-characterized. These
cells can be isolated from the gonadal and inguinal fat pads of mice using extraction
protocols similar to those for human tissue [101]. The multilineage differentiation
potential of mouse ASCs has been confirmed by a number of groups [102-106]. While
detailed comparison studies have yet to be reported in the literature, factors such as
mouse strain, age, sex, and the selected fat depot for extraction are likely to influence
murine ASC differentiation capacity and functionality.

2.2.2

ASC immunophenotype

As previously mentioned, a panel of markers has been defined by IFATS and the ISCT as
a means to standardize the characterization of human ASCs through cell surface
phenotyping (Table 2.1). In general, the ASC cell surface phenotype is similar to
bmMSCs with the exception of CD34, which is highly expressed on human ASCs at
early culture passages, as well as positive expression of CD36 (fatty acid translocase)
[72, 107, 108]. A joint statement from IFATS and the ISCT recommended that flow
cytometric analyses of ASCs include at least two primary positive and two primary
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negative markers, along with secondary positive and negative markers to strengthen the
characterization [81].
Table 2.1. Human ASC cell surface phenotype [81, 108]
Antigen
Primary positive
markers (>80%)

CD90 (Thy-1)
CD105 (endoglin)
CD73 (ecto-5’-nucleotidase)
CD44 (hyaluronic acid receptor)
CD29 (β1-integrin)
CD13 (aminopeptidase-N)
CD34 (progenitor associated marker)*
CD146 (melanoma cell adhesion molecule, MCAM)*
Secondary positive
CD10 (neprilysin)
markers
CD26 (dipeptidyl peptidase-4)
CD49d (α4-integrin)*
CD49e (α5-integrin)
CD36 (fatty acid translocase)
Primary negative
CD31 (platelet endothelial cell adhesion molecule,
markers (<2%)
PECAM)
CD45 (leukocyte-common antigen, LCA)
CD235a (glycophorin A)
HLA-DR (human leukocyte antigen-antigen D related)
Secondary negative
CD3 (T-cell co-receptor)
markers
CD11b (αM-integrin)
CD49f (α6-integrin)
CD106 (vascular cell adhesion molecule 1, VCAM-1)
PODXL (podocalyxin-like)
*variable levels of expression
Cell surface phenotyping of murine ASCs revealed that human ASCs had a similar cell
surface marker expression profile with some exceptions [102, 106, 109-111]. While
considered positive markers in human ASCs, murine ASCs have been reported negative
for CD34 [106, 109, 110] and CD146 [102], with more variable expression levels of
CD105 [106, 109-111].
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2.2.3

ASC differentiation capacity

ASCs are capable of differentiation along the adipogenic, osteogenic, and chondrogenic
lineages [81]. Adipogenic differentiation protocols typically involve the culture of ASCs
at cellular confluence, since close cell-cell contact promotes growth arrest required for
subsequent differentiation [38]. In addition, a cocktail of chemical agents, cytokines, and
hormones are added to the culture media to stimulate adipogenic differentiation. These
supplements include glucocorticoid agonists such as dexamethasone and hydrocortisone,
as well as supra-physiologic concentrations of insulin, which is important for initiating
the induction of ASCs toward the adipogenic lineage [112]. Activation of the early
transcription factors CCAAT/enhancer-binding protein (C/EBP)-β and C/EBPδ
stimulates expression of the primary transcription factors of adipogenesis: C/EBPα and
peroxisome proliferator-activated receptor-gamma (PPARγ) [113]. This in turn
upregulates adipocyte-specific genes, including expression of lipoprotein lipase (LPL),
glucose transporter-4 (GLUT-4), and glycerol-3-phosphate dehydrogenase (GPDH)
associated with lipid accumulation and terminal differentiation [114, 115]. Additionally,
adipogenic media formulations often include synthetic PPARγ ligands such as
rosiglitazone and troglitazone, which can directly stimulate adipogenic gene expression
[116, 117].
Osteogenic differentiation of ASCs can be induced using a variety of media supplements
including beta-glycerophosphate, insulin, vitamin D, dexamethasone, and ascorbate-2phosphate in order to stimulate matrix deposition and mineralization [35, 104, 118]. The
process of osteogenic differentiation begins with a proliferative phase and the formation
of dense cell nodules, followed by ECM production and secretion that is linked to
osteocyte maturation and matrix mineralization [119]. A variety of biochemical signaling
pathways are implicated in osteogenic differentiation, including the canonical Wnt and
bone morphogenic protein (BMP) signaling pathways, as well as the signaling mothers
against decapentaplegic (SMAD) phosphorylation pathway [120, 121].
To stimulate chondrogenic differentiation, ASCs are cultured in 3D aggregates in order to
enhance cell-cell and cell-ECM interactions and to mimic the mesenchymal condensation
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process during embryogenesis [122]. Chondrogenic media formulations often include
factors such as insulin, transforming growth factor-beta (TGF-β), dexamethasone, and
ascorbate-2-phosphate in order to further stimulate the process of chondrogenic
differentiation [104, 123]. Differentiation is initiated with the upregulation of the
transcription factor sex-determining region Y-related high motility group box 9 (SOX9)
transcription factor, the master regulator of chondrogenesis [122]. The combined SOX9
activation and cellular condensation prompts the formation of pre-chondrocytes, followed
by further maturation toward proliferating chondrocytes, linked to a shift from collagen I
to collagen II expression along with the production of other cartilage ECM proteins
including aggrecan, collagen IX, and collagen XI [124]. Late stages of chondrogenic
differentiation are associated with increased expression of runt-related transcription
factor 2 (RUNX2) and formation of pre-hypertrophic chondrocytes, followed by terminal
differentiation into hypertrophic chondrocytes [125].

2.2.4

ASC paracrine functions

In addition to their capacity to differentiate along multiple cell lineages, ASCs can secrete
beneficial paracrine factors to stimulate host-derived tissue regeneration [126, 127].
These include a wide array of cytokines and growth factors that can modulate the
immune response, as well as promote cell survival and angiogenesis [101]. In particular,
the immunomodulatory effects of MSCs have received growing interest, and while these
effects have been better characterized in bmMSCs, several studies have indicated that
bmMSCs and ASCs may display similar immunomodulatory functions [128-131]. The
immunoregulatory capacity of ASCs has mainly been studied in association with
monocytes/macrophages and T cells, and is primarily mediated by the secretion of
cytokines that include IL-10, IL-13, prostaglandin E2, indoleamine 2,3-dioxygenase
(IDO), hepatocyte growth factor (HGF), and leukemia inhibitory factor (LIF) [132, 133].
In assessing the influence of ASCs on the macrophage response, studies typically
examine the effects of ASCs on macrophage phenotype. In a classification system
analogous to the Th1/Th2 system for T lymphocytes, macrophage phenotypes have been
broadly classified along a spectrum that includes M1-polarized “pro-inflammatory”
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macrophages, and M2-polarized “anti-inflammatory” or “pro-regenerative” macrophages
[134]. As such, several in vitro co-culture studies have indicated that ASCs may
modulate inflammation by promoting a shift toward an M2-like macrophage phenotype
through contact-independent mechanisms [7-10]. These findings have been confirmed in
animal models [9, 135], including a study in which ASCs incorporated into human fat
grafts implanted in an athymic mouse model augmented the expression of the M2
macrophage markers CD163 and CD206 after 14 days [11]. A potential role for
exosomes and microRNAs released by MSCs has also been implicated in regulating
macrophage phenotype [136]. Wang et al. reported that miR-223 release by mouse
bmMSCs was important for suppressing pro-inflammatory cytokine secretion by
lipopolysaccharide-stimulated macrophages, and was crucial to the cardioprotective
effects of bmMSC-derived exosomes in a polymicrobial sepsis mouse model [136]. In
addition to modulating macrophage phenotype, MSCs have been shown to recruit
monocytes/macrophages through secretion of chemokines, including chemokine (C-C
motif) ligand (CCL)-2,3,4,7 and -12 within the tumour microenvironment as well as in
wound healing [12, 13].
The immunomodulatory role of ASCs has also been demonstrated through cross-talk with
T cell populations. In particular, ASCs have been shown to inhibit T cell activation and
pro-inflammatory cytokine production, as well as augment levels of regulatory T cells
[137]. Pro-inflammatory cytokines have been associated with increased expression of
immunosuppressive factors by MSCs [137, 138]. For example, interferon-gamma (IFNγ)
stimulation of human ASCs has been shown to augment their expression of IDO [139]
and prostaglandin-E2 [140], which in turn suppress T cell proliferation in direct and
indirect co-culture models. Interestingly, the immunosuppressive functions of ASCs have
enabled their use in both allogeneic and xenogeneic animal models without the need for
immunosuppressants [141]. Moreover, these properties have prompted the use of
allogeneic ASCs for the treatment of acute graft-versus-host disease, showing beneficial
outcomes as a salvage therapy in steroid-refractory patients [142-144]. Importantly, Lai
et al. demonstrated that human ASCs at passage 3 inhibited proliferation of IL-17producing CD4+ T cells from patients with systemic lupus erythematosus, while passage
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8 cells had the opposite effect [145], suggesting that in vitro expansion of ASCs may
influence their immunomodulatory capacity.
Anti-apoptotic and angiogenic factor secretion by ASCs has also been reported, including
factors such as VEGF, HGF, TGF-β, and platelet-derived growth factor (PDGF) [146,
147]. In support of this, the administration of allogeneic ASCs lead to improved
neovascularization in mouse models for hindlimb ischemia through indirect paracrine
mechanisms involving the secretion of pro-angiogenic factors [148-151]. These
observations have been corroborated in a variety of other models for ischemic diseases
(recently reviewed by Zhao et al. [152]). An important role for HGF in mediating these
responses has also been identified. Downregulation of HGF expression through RNA
interference impaired the ability of human ASCs to promote the survival, proliferation,
and migration of mature and progenitor endothelial cells in vitro, as well as their ability
to promote reperfusion in a nude mouse hindlimb ischemia model [153].

2.3 The ECM and tissue decellularization
2.3.1

The ECM

The ECM is a complex network of proteins and polysaccharides with tissue-specific
composition and architecture, consisting of cell-secreted structural and functional
molecules that are essential for providing physical support and modulating cell signaling
within tissues [154]. There are two main types of ECM: the basal lamina and the
interstitial matrix. The basal lamina is a highly bioactive mesh-like network that
functions as a base for cell-attachment and as a mechanical barrier in epithelial tissues
[155]. The interstitial matrix helps to define the 3D structure of a tissue and consists of
structural and bioactive components that are secreted by resident cells [156]. The ECM is
a crucial component of the cellular microenvironment as it dynamically mediates cellular
functions [156].
In general, the ECM is comprised of fibrous proteins, glycoproteins, glycosaminoglycans
(GAGs), and proteoglycans; however, the proportion of these components, their
organization and/or the presence of specialized macromolecules varies across tissues
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[154]. Fibrous proteins in the ECM include collagen and elastin, which provide structural
support to the tissue. Collagen is the most abundant protein in mammals and includes 28
subtypes that function to provide structural integrity, strength, and stability to the ECM
[157]. Elastin is another key structural protein that contributes to the elastic properties of
soft tissues, particularly within the skin, lungs, and blood vessels [158]. Glycoproteins are
another important component of the ECM; these proteins are covalently bound to mono-,
di-, or oligosaccharides and function to promote cell attachment and link ECM
components [159]. Additionally, GAGs and proteoglycans serve critical roles within the
ECM. GAGs are long unbranched polysaccharides consisting of a repeating disaccharide
unit, while proteoglycans are a subclass of glycoprotein defined by their covalent linkage
to one or more sulphated GAG chains [158]. The highly charged nature of GAGs and
proteoglycans functions to attract and bind water molecules within the ECM, as well as to
sequester growth factors [160].
Further specialization of the ECM is demonstrated by the ability of cells to dynamically
alter ECM components in order to meet the metabolic and mechanical demands of the
tissue [161]. Within the context of tissue repair, ECM dynamics are similarly important
as the ECM is known to regulate the diverse array of cell types involved at all stages of
wound healing [162]. Turnover of ECM components is mediated by a balance of ECM
synthesis by the cells within the tissue, and matrix degradation through cell-secreted
enzymes such as matrix metalloproteinases (MMPs) and ADAMs (a disintegrin and
metalloproteinase) family members, which degrade ECM components [163]. Moreover,
secretion of tissue inhibitors of metalloproteinases (TIMPs) serves as an additional level
of control by inhibiting MMP function, allowing for tight regulation of matrix dynamics
[164]. This complex interrelationship between cells and the ECM is essential for
maintaining normal tissue homeostasis, as dysregulation has been associated with a
variety of pathologies including liver cirrhosis, pulmonary fibrosis, and cancer [165,
166].
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2.3.2

Tissue decellularization

Recognizing the importance of the 3D microenvironment in mediating cell function both
in vitro and in vivo, there has been growing interest in the design of cell-instructive
biomaterials platforms to help direct cell behavior and promote tissue regeneration [167170]. As the complexity of the native ECM cannot be easily replicated using synthetic
materials, a growing body of work has examined the use of scaffolds derived from
decellularized tissues as cell culture and delivery vehicles [171, 172]. Decellularized
scaffolds are fabricated using customized protocols designed to extract antigenic cellular
components – including organelles, lipids, nucleic acids, and membraneassociated/cytosolic proteins – to obtain a complex ECM enriched in structural proteins.
These scaffolds are bioactive and inherently biodegradable, allowing for matrix
remodelling and integration into host tissues. Thus, decellularized materials are an
attractive platform for tissue engineering strategies due to their potential to stimulate in
situ tissue regeneration. Several decellularized ECM products are currently in clinical
use, including those derived from human or animal small intestinal submucosa (SIS),
bladder, dermis, and heart valves [173].

2.3.3

Decellularized adipose tissue scaffolds

DAT scaffold fabrication was first reported by the Flynn laboratory in 2010 as a
biomaterial platform for soft tissue engineering strategies [5]. Human adipose tissue is a
rich source of ECM, and is frequently discarded as surgical waste; therefore, fat
represents an abundant and economical alternative to xenogeneic-sourced tissues for
decellularized materials [5]. Since the original 2010 report, decellularization protocols for
human adipose tissue have been developed by a number of other groups [34, 174-177]. In
general, these protocols involve initial freeze/thaw cycles in hypotonic salt solutions to
promote cell lysis, coupled with isopropanol or other polar solvents to solubilize cellular
components and lipids within the tissue [177]. Further, enzymatic treatment with trypsin/
ethylenediaminetetraacetic acid (trypsin/EDTA), DNase, and RNase serves to release
cells and degrade nuclear components. While the majority of adipose tissue
decellularization protocols involve the use of detergents to extract lipids and cellular
components, the Flynn laboratory protocol is uniquely detergent-free [5]. The lack of
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detergents in the Flynn protocol is an effort to better preserve ECM composition [5],
since these agents can cause marked reductions in more soluble ECM components such
as GAGs [178, 179] and growth factors [180], and residual detergents may have
cytotoxic effects.
DAT scaffolds fabricated using the Flynn methods provide an inductive
microenvironment for the adipogenic differentiation of ASCs in vitro [181], as well as for
in vivo fat formation [4]. More specifically, ASCs cultured on the scaffolds upregulated
the expression of the adipogenic genes PPARγ and C/EBPα in the absence of exogenous
growth factors [181]. When cultured in adipogenic differentiation media, ASCs seeded
on DAT scaffolds displayed high levels of GPDH enzyme activity and adipogenic gene
expression relative to 3D cell aggregate and 2D monolayer culture controls [181].
Moreover, DAT scaffolds have been shown to support angiogenesis and adipogenesis
within an immunocompetent subcutaneous Wistar rat model, and pre-seeding of the
scaffolds with allogeneic ASCs further enhanced tissue remodeling [4]. Using a different
DAT preparation protocol, Wang et al. showed that unseeded DAT scaffolds also
supported adipogenesis and neovascularization in a subcutaneous Fischer rat model
[174].
In addition to the use of DAT in its intact form, the Flynn laboratory has developed
methods to incorporate the DAT as a cell-instructive component in a variety of scaffold
formats suited to different tissue engineering applications. For example, microporous
foams derived from α-amylase-digested DAT have demonstrated a potent angiogenic
response along with gradual resorption in a subcutaneous immunocompetent Wistar rat
model, which would be favourable for use in wound healing applications [182]. The
Flynn laboratory also developed DAT-based microcarriers as a stem cell expansion
platform and injectable biomaterial [183-185], as well as injectable hydrogel composites
for localized cell delivery and treatment of small volume adipose tissue deficits [186188]. In assessing the adipogenic differentiation of ASCs, the pro-adipogenic properties
of the DAT-based biomaterials were conserved across the full range of scaffold formats
[5, 182-184, 187, 188], supporting the importance of scaffold composition in directing
tissue-specific differentiation. DAT-based hydrogel composites have also been developed
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by a number of other groups [176, 189, 190], including a protocol incorporating
decellularized human lipoaspirate [177].

2.4 Stem/progenitor cells and ECM-derived scaffolds for
tissue engineering
Stem/progenitor cells are of great interest in the fields of tissue engineering and
regenerative medicine due to their innate ability to self-renew and differentiate along
multiple lineages. From a translational perspective, the poor localization, retention and
survival of cells delivered in suspension points to the need for rationally-designed cell
delivery systems with properties tuned to the target site for regeneration [191-193]. As
such, decellularized materials may act as promising cell delivery vehicles to guide
stem/progenitor cell-mediated regeneration [63]. In the following section, the use of
stem/progenitor cells and ECM-derived scaffolds for tissue engineering strategies is
discussed, with emphasis on the potential for decellularized materials to modulate
stem/progenitor cell behaviour.

2.4.1

Stem/progenitor cell sources and seeding strategies for
ECM-derived scaffolds

A variety of stem/progenitor cell types have been explored for use in tissue engineering
strategies. Depending on the stem/progenitor cell source and the tissue of interest, the
recellularization of ECM-derived scaffolds with stem/progenitor cells may enable
repopulation with a range of cell types through engraftment and differentiation or
enhancement of tissue regeneration through indirect paracrine mechanisms [126, 127]. In
the following discussion, emphasis will be placed on studies investigating MSCs, as these
have been most commonly studied for regenerative applications [194], are readily
accessible, and have the potential to be used autologously or allogeneically [195-197].
The goal in recellularization of ECM-derived scaffolds is to repopulate the ECM with
appropriate cell numbers and distribution in order to recapitulate the spatial organization
and density of cells in the native tissues, while taking into account the variety of cell
types that may be required. Methods for recellularization are designed based on the tissue
type and selected application (reviewed in [198, 199]). In general, recellularization can be
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completed in culture prior to implantation or can rely on the infiltration of host cells. In
the simplest approach, cell seeding can be achieved statically, by allowing cells to
passively settle onto the scaffold. Alternatively, dynamic seeding involving the infusion
of cells into the scaffold through mechanical agitation or perfusion can be applied. In
addition, some seeding strategies take advantage of residual vessel lumens within the
scaffold as a means of cell delivery [199].

2.4.2

Stem/progenitor cell-instructive effects of decellularized
scaffolds

In this section, “stem/progenitor cell-instructive effects” of ECM-derived scaffolds are
defined as any cellular response to the material that may ultimately aid in tissue
regeneration. By this definition, decellularized ECM can instruct stem or progenitor cell
behaviour through a variety of direct and indirect means, such as by mediating
stem/progenitor cell adhesion, migration, proliferation, paracrine factor production,
and/or differentiation (Figure 2.1). A common challenge that has been encountered in
strategies attempting to deliver stem cells in suspension is that of poor long-term cell
viability, which may be related to the loss of cell adhesion leading to anoikis, or to harsh
conditions within the target microenvironment [200, 201]. Consequently, ECM-derived
scaffolds have been explored as potential cell delivery platforms to enhance
stem/progenitor cell adhesion, viability, and proliferation. Indeed, Sharma et al., have
shown in a baboon bladder regeneration model that autologous green fluorescent protein
(GFP)-labelled bmMSCs seeded on decellularized porcine SIS scaffolds displayed high
expression levels of the proliferation marker Ki-67 within the implant region at 10 weeks
post-implantation [202]. Similarly, decellularized porcine SIS scaffolds showed
significantly improved survival and proliferation relative to cell delivery alone, as
evidenced by bioluminescence imaging of donor syngeneic luciferase+ murine ASCs
seeded onto the scaffolds in a murine excisional wound model [203]. By promoting
stem/progenitor cell retention and survival, ECM-derived scaffolds may allow these cells
to have increased therapeutic efficacy, while providing an inductive substrate that could
potentially direct differentiation and/or paracrine factor production, as discussed in
greater detail below.
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Figure 2.1. Stem/progenitor cell-instructive effects mediated by ECM-derived
scaffolds. ECM-derived scaffolds can influence stem/progenitor cell adhesion, migration,
viability, proliferation, and differentiation along multiple lineages. Moreover, these
scaffolds can influence stem/progenitor cell secretion of paracrine factors to promote
angiogenesis, and modulate the immune response. VEGF: vascular endothelial growth
factor; ANG-1: angiopoietin-1; PDGF: platelet derived growth factor; IL-6: interleukin
6; IL-10: interleukin 10; TNF-α: tumor necrosis factor-alpha.
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A wide array of studies have reported that donor stem/progenitor cells can enhance tissue
regeneration in ECM-derived scaffolds. In addition, there is a growing body of literature
that supports the use of seeded stem or progenitor cell populations as potentially directly
contributing to tissue regeneration through engraftment and differentiation. In particular,
tissue-specific ECM has been widely postulated to promote lineage-specific
differentiation in vitro. This has been supported through work of the Flynn laboratory
using DAT scaffolds and ASCs [5, 182-184, 187, 188]. Similar results have been
demonstrated by a number of other groups comparing a variety of ECM sources, showing
tissue- and region-specific differentiation of stem or progenitor cells [204-207].
While stem/progenitor cells have the potential to contribute to new tissue development
through differentiation, there is evidence to suggest that the predominant mechanism of
regeneration for MSC populations is indirect through the secretion of beneficial paracrine
factors that promote the establishment of a more conducive milieu for host tissue
regeneration [126, 127]. Key studies demonstrating the immunomodulatory and proangiogenic functions of MSC populations seeded within decellularized tissue
bioscaffolds are discussed below. In all cases, it is important to note that the overall
response of stem/progenitor cells to ECM-derived scaffolds in vivo will also be mediated
by reciprocal signaling and action of host cells that infiltrate the scaffolds following
implantation, including immune cells such as macrophages, and host-derived progenitors.
As previously discussed, MSC populations, including those derived from adipose tissue,
secrete a variety of angiogenic, immunomodulatory, and cytoprotective factors, and these
can play a central role in mediating tissue regeneration [126, 127]; however, few studies
have systematically examined the impact of ECM-derived scaffolds on the
stem/progenitor cell secretory profile. There is emerging evidence to suggest that ECMderived scaffolds may help to provide a supportive microenvironment for stem/progenitor
cell paracrine factor production. In support of this, the Flynn laboratory demonstrated in
an immune-competent rat subcutaneous implantation model that seeding human DAT
with allogeneic rat ASCs modulated the macrophage phenotype, increasing the relative
fraction of infiltrating macrophages that expressed the pro-regenerative M2 macrophage
marker CD163 [4]. The study also reported enhanced angiogenesis and host-derived
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adipose tissue formation within the ASC-seeded bioscaffolds suggesting that the ASCs
contributed to tissue regeneration through indirect paracrine mechanisms [4]. Moreover,
using a rat bladder reconstruction model, Pokrywczynska et al. demonstrated differential
cytokine production in the implant region of decellularized rat bladder matrix seeded with
allogeneic bmMSCs as compared to unseeded implants or MSCs delivered alone [208].
The authors reported a qualitative increase in anti-inflammatory cytokine production
observed by immunohistochemistry in parallel with improved tissue regeneration within
the seeded versus unseeded scaffolds [208]. Other groups have demonstrated that seeding
decellularized porcine SIS [209] or decellularized rat spinal cord [210] with allogeneic
bmMSCs decreased macrophage and/or T cell infiltration in comparison to unseeded
controls in a porcine epicardial patch model and rat spinal cord injury model,
respectively.
In terms of angiogenic factor production, Nie et al. demonstrated that rat ASCs cultured
on decellularized human dermal ECM sheets (AlloDerm®) secreted significant quantities
of VEGF, HGF, TGF-β, and basic fibroblast growth factor (bFGF) in vitro [211]. Using a
diabetic rat excisional wound model, the same study reported increased CD31+ blood
vessel density and augmented protein levels of these angiogenic factors within seeded
scaffolds as compared to unseeded controls. A number of other groups have also
provided histological and immunohistochemical evidence that seeding decellularized
scaffolds with MSCs improves neovascularization in vivo as compared to unseeded
controls [4, 208, 212-215].

2.4.3

Mechanisms of stem/progenitor cell modulation by ECMderived scaffolds

The compositional, biomechanical, and structural properties of the ECM are unique to a
given tissue and each can play an integral role in mediating cell behaviour. Decellularized
bioscaffolds can be designed to retain some of these properties and modulate the
behaviour of stem/progenitor cells by re-capitulating properties of the native stem cell
niche (summarized in Figure 2.2). However, it is important to recognize that it can be
extremely challenging to decouple the individual effects of the compositional,
biomechanical, and structural properties of the scaffold, as they are closely linked and the
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scaffolds have innate heterogeneity. In addition, there is a dynamic interrelationship
between the stem/progenitor cells and these engineered cellular microenvironments.
Seeded or infiltrating regenerative cell populations will sense and respond to the ECM
within the decellularized tissues, and in turn remodel the scaffolds via the action of MMP
and ADAM family members, as well as through the synthesis of new matrix components
[216]. The properties of the remodeled ECM may be extensively altered through these
cell-ECM interactions, which can subsequently impact the downstream cellular response
[162, 163].
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Figure 2.2. Proposed mechanisms by which compositional, biomechanical, and
structural properties of ECM-derived scaffolds direct stem/progenitor cell
behaviour and responses. A) Stem/progenitor cells may interact with the scaffold
directly through receptor-ligand binding or indirectly through binding of growth factors
and/or cryptic peptides released by proteases that degrade the ECM. These cell-ECM
interactions may in turn influence paracrine factor secretion by the cells. B)
Biomechanical properties of the scaffold influence mechanical forces transmitted via the
cytoskeleton to alter cell responses through mechanotransduction pathways. C) Scaffold
porosity governs the surface area available for cell-ECM contacts, as well as the degree
of cell-cell contact. Surface topography and molecular functionality influence host cell
and protein binding. Vascular networks and basement membranes may be conserved after
decellularization, and may play a role in cellular organization.

25

Similar to the importance of ECM components in directing cellular processes within the
native stem cell niche [217], during regeneration [218] and in pathological conditions
[219], the complex ECM composition within decellularized scaffolds likely plays a key
role in influencing stem/progenitor cell behaviour. Indeed, the retention of structural and
functional proteins in decellularized tissues has been demonstrated by a number of
research groups [220-223]. For example, a recent study from the Flynn laboratory
employed mass spectrometry-based screening to compare the protein content of the DAT
with human decellularized cancellous bone (DCB) [21]. Through the use of a novel
processing method involving treatment of protein extracts with purified collagenase to
deplete highly-abundant collagen and enable detection of lower abundance proteins, the
study demonstrated that the DAT and DCB extracts were compositionally distinct,
identifying 804 and 1210 proteins, respectively, in the collagenase-treated samples [21].
The DAT was shown to include a diverse range of non-structural bioactive ECM
components and a variety of adipogenic proteins that were consistently more highly
expressed in the DAT compared to the DCB [21].
While scaffold composition may influence stem/progenitor cell behaviour via direct
binding of the cells to bioactive ECM components, another potential mechanism could
involve the action of ECM degradation products, termed matrikines [224]. In native
tissues, matrikines are generated through the proteolytic action of MMP and ADAM
family members [216], and are known to recruit stem/progenitor cells, as well as
modulate cell adhesion, migration and differentiation [225-227]. Examples of these
“cryptic peptides” include the Arg-Gly-Asp (RGD) peptide derived from fibronectin and
collagen, which promotes cell adhesion [216], as well as the hydrophobic sequences
VGVPG and VGVAPG derived from elastin, which stimulate smooth muscle cell
proliferation [228] and fibroblast, monocyte, and macrophage chemotaxis [229]
respectively. Fragments of other ECM products such as hyaluronic acid generated during
tissue injury and inflammation have been shown to stimulate angiogenesis and MMP
production [216], as well as modulate macrophage phenotype [230]. Further, retained
glycosaminoglycans (GAGs) within the decellularized tissues can bind and sequester
soluble growth factors, regulating their availability and activity [231]; MMP degradation
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of the ECM may trigger their release, allowing for dynamic regulation of stem/progenitor
cell behaviour [217].
In addition to scaffold composition, the biomechanical properties of ECM-derived
scaffolds can influence cell behaviour. The biomechanical properties of native ECM vary
greatly across tissues [232] and are known to influence stem cell adhesion, proliferation,
migration and differentiation [217, 233]. Cells are able to sense mechanical forces
through cell adhesion complexes that can activate signaling cascades to influence cell
behaviour [234]. For example, mechanotransduction through integrin binding to the ECM
can activate downstream focal adhesion kinase (FAK) and phosphoinositide 3-kinase
(PI3K) pathways, which regulate stem cell self-renewal [235, 236]. While the effects of
ECM-derived scaffold biomechanical properties on stem/progenitor cell function have
not been well-studied to date, previous work with synthetic hydrogel platforms suggests
that mimicking the biomechanical properties of the native tissues may help to direct
lineage specification. In 2D culture studies on collagen-containing polyacrylamide gels,
human bmMSCs demonstrated enhanced expression of neurogenic markers on soft
matrices simulating the stiffness of brain (0.1 – 1 kPa), myogenic markers on
intermediate matrices simulating the stiffness of muscle (8 – 17 kPa), and osteogenic
markers on the stiffest substrates studied (25 – 40 kPa) [237]. In further support of this,
the pro-adipogenic properties of the DAT may be related to its biomechanical properties,
as previous characterization studies from our laboratory have shown that DAT sourced
from a range of human fat depots displayed elastic, hyperelastic, and deformation
patterns similar to that of native breast adipose tissue [22, 23].
The molecular and three-dimensional architecture of decellularized scaffolds is likely
another key mediator of stem/progenitor cell behaviour. Notably, Brown et al. showed
that decellularized scaffolds derived from a variety of tissue types displayed distinct
structural and morphological differences, demonstrating the tissue-specificity of these
features [238]. Certain structural features, such as the basement membrane, which can be
conserved following decellularization, have been shown to guide cell migration and
growth patterns [239]. Other parameters such as scaffold porosity could impact the
cellular response by facilitating nutrient and oxygen diffusion, as well as by modulating
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cell-cell and cell-ECM interactions that can influence cell adhesion, migration,
proliferation, and differentiation [240, 241]. In particular, cell density and shape are wellrecognized mediators of stem cell lineage commitment [242], and may be important
factors in modulating the response of stem/progenitor cells seeded on decellularized
bioscaffolds. For example, in comparing the adipogenic differentiation of human ASCs in
composite hydrogels incorporating DAT particles of varying sizes (278 ± 3 μm vs. 38
± 6 μm), the Flynn laboratory showed that adipogenic differentiation was enhanced in the
scaffolds containing small particles and a higher cell density, which was postulated to be
due to enhanced cell-cell interactions in the ASCs clustered around the smaller particles
[187].

2.5 Host response to biomaterials in tissue engineering
There has been growing interest in the role of the host response and specific immune cell
populations in tissue engineering applications. Historically, the development of implanted
biomaterials has focused on the use of “inert” materials to minimize the interaction of the
material with host cell populations [243]. However, a major limitation of these materials
is their tendency to promote fibrous encapsulation of the implant through excessive
matrix deposition by fibroblasts, macrophages, and other cell types involved in the
foreign body reaction [244]. For example, biologically inert titanium implants used in
orthopedic and oral/maxillofacial surgeries can pose issues of fibrous encapsulation
which can negatively impact the long-term stability of the implant and lead to periimplant bone resorption [245, 246]. Recognizing the complex physiological response
involved in tissue injury and healing, there has been a shift toward the design of bioactive
materials that selectively interact with host immune cell populations in order to promote
the integration and remodeling of these materials with the surrounding tissues.

2.5.1

Overview of the host response to biomaterials

The implantation of a biomaterial triggers a cascade of events involving a wide array of
cell types and secreted factors. Adsorption of coagulation factors and complement
proteins to the material begins immediately within seconds of implantation [247].
Coagulation factors include components of both the intrinsic and extrinsic coagulation
28

cascades, initiated by factor XII and tissue factor, respectively [248, 249]. Binding of
these factors leads to downstream platelet activation and thrombin formation on the
implant surface [249, 250]. At the same time, activation of the complement cascade
occurs upon contact with the biomaterial via the classical, alternative, and lectin
pathways [251, 252]. Together, the coagulation and complement systems interact with
and regulate each other synergistically, leading to the recruitment and activation of
inflammatory cells [253]. Moreover, endogenous danger signals known as alarmins are
released by the nearby tissues that are inevitably damaged upon surgical implantation of
the material [247, 254]. Alarmins include molecules such as adenosine triphosphate
(ATP), uric acid, and fibrinogen, as well as cleaved ECM components such as collagen
peptides, hyaluronic acid, and fibrinogen [254]. These factors interact with pattern
recognition receptors that contribute to leukocyte recruitment and inflammation [254,
255]. Given that ECM proteins can directly mediate leukocyte binding via integrins
[256], this represents another likely mechanism whereby immune cell recruitment occurs
in ECM-derived scaffolds. In support of this, Uzarski et al. demonstrated the adhesion of
platelets, leukocytes, and endothelial cells to decellularized human umbilical vein
scaffolds in vitro with differential levels of adhesion to scaffolds prepared using four
different decellularization protocols [257].
The combined events related to the coagulation and complement cascades and release of
alarmins are followed by recruitment of circulating granulocytes including neutrophils
and mast cells to the biomaterial implant [258]. In particular, neutrophils are central to
the initial host response, functioning to phagocytose debris, produce cytotoxic reactive
oxygen species, and release granules containing proteases and other factors [259].
Through a process termed NETosis, neutrophils are also known to release neutrophil
extracellular traps (NETs), decondensed chromatin enriched in antimicrobial agents that
act to trap and kill microbes while minimizing damage to host cells [260]. Neutrophils
are thought to persist for very short time points less than three days following injury;
longer durations are typically associated with an adverse immune response and increased
severity of inflammation [261]. However, in mouse models, neutrophils have also been
shown to persist for several weeks within models of tissue repair [262].
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In addition, there is increasing evidence that neutrophil phenotypes can be adapted based
on the microenvironment and that these cells can modulate the downstream response of
macrophages, dendritic cells, and T cells [263]. For example, mouse neutrophils have
been shown to produce IL-10, an anti-inflammatory cytokine associated with modulating
macrophage phenotype and suppressing the pro-inflammatory functions of other immune
cells [264, 265]; however, IL-10 production by human neutrophils is controversial [263,
266, 267]. Neutrophils have also been shown to be capable of suppressing T cell
activation and proliferation through the production of hydrogen peroxide, arginase, and
nitric oxide synthase 2 [268-270]. Little is known regarding which biomaterial
characteristics may induce a favourable neutrophil response; however, this represents an
active area of research due to increased recognition of their functional heterogeneity
[271]. In addition to neutrophils, mast cells have been identified as another key
granulocyte involved in the initial response to polymer-based biomaterials, with
degranulation and histamine release linked to the foreign body reaction through
recruitment of fibroblasts, macrophages, and other granulocytes in mice and humans
[272-275].
Following the recruitment of granulocytes, other immune cells begin to infiltrate the
biomaterial. Among these, macrophages are of predominant interest in tissue engineering
due to their high degree of plasticity and their diverse roles at multiple stages of tissue
repair (discussed in greater detail in the following section). T cells have also been shown
to infiltrate ECM-derived scaffolds in animal models by a number of groups [209, 210,
276]. Wang et al. recently reported on the use of humanized mice to investigate the T cell
response to subcutaneously injected hydrogels derived from porcine or human cadaveric
decellularized myocardium [277]. The authors demonstrated that both the xenogeneic and
allogeneic ECM elicited a shift from cytotoxic CD8+ T cell infiltration on day 3 postimplantation, to predominantly CD4+ T helper cells on day 7. While increased T cell
recruitment was observed in the xenogeneic porcine ECM-derived scaffold, both
materials promoted a shift toward a constructive pro-remodeling Th2 phenotype.
Other infiltrating immune cells include dendritic cells and myeloid-derived suppressor
cells. These cells have not been well-studied with respect to the host response to
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biomaterials, but are likely to play a role. Dendritic cells are antigen presenting cells that
activate T cells and natural killer (NK) cells and display immunoregulatory functions by
inducing T cell anergy, antigen-specific tolerance, as well as activation of regulatory T
cells [278]. Naturally-derived biomaterials including alginate, chitosan, and agarose have
been shown to induce differential effects on dendritic cell maturation and activation, with
some studies reporting pro-inflammatory responses, and others demonstrating protolerogenic effects [279, 280]. Myeloid-derived suppressor cells are a heterogeneous
population of myeloid cells and are also known to act as potent suppressors of T cell
activation [281]. The contribution of these cells in the context of tissue engineering has
not been studied, but both are implicated as key players in the resolution of inflammation
and subsequent tissue repair [282, 283].

2.5.2

Macrophage response to biomaterials and role in tissue
engineering

Macrophages have recently gained considerable attention in the field of tissue
engineering. Macrophages are phagocytic innate immune cells derived from a common
myeloid progenitor (CMP) in the bone marrow [284]. Stimulation of CMPs through a
cytokine cascade that includes granulocyte-macrophage colony stimulating factor (GMCSF), granulocyte colony stimulating factor (G-CSF), and macrophage colony
stimulating factor (M-CSF) leads to their eventual differentiation into monocytes which
enter the circulation [284]. Circulating monocytes are a heterogeneous group of cells with
at least three existing subset populations [285]. CD14hiCD16- monocytes in humans
(Ly6chighGr1+ cells in mice) are considered “classical inflammatory monocytes” that
rapidly migrate to tissues upon injury or infection in response to receptor/ligand
interactions involving C-C chemokine receptor (CCR)-2 on monocytes and the
chemokine CCL2 [285]. In contrast, CD14+CD16+ monocytes in humans (Ly6clowGr1- in
mice) are “nonclassical monocytes”; these cells lack CCR2 expression and function to
patrol the vasculature and clear damaged endothelial cells [285]. Humans also have a
third subset of monocytes, the intermediate subset defined as CD14-/lowCD16+ that are
also involved in inflammatory responses [285]. It is unclear whether there is an
equivalent subset in mice [285].
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Upon extravasation into tissues, monocytes differentiate into macrophages [284]. These
cells display distinct phenotypic profiles based on the tissue type and surrounding
microenvironment. Macrophage phenotypes have been broadly classified along a
spectrum that includes M1-polarized classically-activated macrophages, and M2polarized alternatively-activated macrophages [134]. These definitions are largely based
on in vitro studies and they continue to evolve with further investigation into the roles
and function of these cells in vivo [286]. Nonetheless, the M1/M2 classification system
represents a useful construct for discussing the diversity of macrophage functions in vivo.
In general, M1-polarized macrophages can be induced by IFNγ, lipopolysaccharide, and
TNFα, and are considered pro-inflammatory cells that secrete reactive oxygen species
and cytokines that include IL-1β, IL-6, and TNFα [134]. In contrast, M2-polarized
macrophages are induced by IL-4, IL-10, and IL-13, as well as glucocorticoids, and are
associated with the resolution of inflammation, as well as tissue repair [134]. M2
macrophages have been further categorized into M2a, M2b, and M2c subtypes based on
their stimuli for differentiation and molecular marker expression profiles [287, 288].
Each of these subtypes are associated with immunoregulatory functions through secretion
of IL-10 and other subtype-specific cytokines, and may be present in varying numbers
based on the time course of tissue repair, and the interstitial cytokine milieu [287]. For
example, M2c macrophages are induced by IL-10 and glucocorticoids, and express the
receptors CD163 and CD206 [287, 289]. This subpopulation is involved in matrix
deposition and tissue remodeling through MMP secretion, as well as regulating
inflammation through IL-10 and TGF-β secretion [287, 289]. The plasticity of
macrophages has been demonstrated in vitro through experiments in which M1- or M2polarized macrophages have been induced to express markers of the opposing phenotype
[290, 291]. However, whether or not macrophages display similar phenotypic changes in
vivo is controversial, with some studies supporting this concept [292-294], while others
suggest that the macrophage subsets arise from different populations of infiltrating
monocytes [295-297].
Within the context of tissue repair, both M1 and M2 macrophages are thought to play an
integral role at multiple stages of healing. In cutaneous wound healing, initial infiltration
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of M1-like macrophages is thought to be important for clearance of pathogens and debris,
followed by a shift toward M2 macrophages that regulate the inflammatory response and
promote tissue formation and remodeling [286, 298, 299]. Involvement of both M1 and
M2 cells is thought to be crucial; for example, in the process of angiogenesis, M1
macrophages have been shown to initiate vessel sprouting, while M2 macrophages
mediated vascular remodeling, anastomosis, and recruitment of pericytes [300].
In tissue engineering, the macrophage response to biomaterials is central to the
regenerative process. As mentioned, a major issue that has been encountered in the use of
synthetic implants is the tendency for the material to become encapsulated in an almost
avascular sheath of connective tissue [301]. Macrophages are implicated in this foreign
body response through a process known as “frustrated phagocytosis”, in which the
inability of the macrophages to phagocytose the material due to limited biodegradability
and size restrictions leads to cell fusion and formation of multinucleate bodies along the
implant periphery [301]. In contrast, the response to ECM-derived scaffolds is markedly
different, allowing for cell infiltration and interaction with bioactive ECM components.
Similar to the native repair process, several groups have indicated through in vivo studies
that ECM-derived scaffolds promote a shift from the expression of M1 macrophage
markers at early time points, to expression of M2 markers over time [302-304]. Indeed,
Brown et al. have shown through the comparison of 14 ECM-derived surgical mesh
materials implanted in the rat abdominal wall that increased numbers of M2-like
macrophages and a higher ratio of M2:M1 macrophage markers at 14 days postimplantation served as a statistical predictor of constructive tissue remodeling assessed
by histomorphometry at 14 and 35 days post-implantation [305]. A possible mechanism
through which decellularized scaffolds may modulate the immune response could involve
ECM degradation products, as treatment of bone marrow-derived mouse macrophages
with pepsin-digested porcine decellularized SIS promoted an M2 macrophage phenotype
[306]. A recent study by Londono et al. pointed to the influence of incomplete
decellularization on macrophage phenotype demonstrating that collagen scaffolds
supplemented with varying concentrations of DNA, mitochondria, or cell membrane
remnants stimulated expression of M1 macrophage markers in a dose-dependent manner
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after implantation in an abdominal wall defect rat model [307], emphasizing the
importance of careful characterization of decellularized scaffolds.

2.6 Summary
Adipose-derived stem/stromal cells have been investigated as a regenerative cell source
capable of multilineage differentiation in vitro, as well as the secretion of beneficial
paracrine factors that may aid in tissue repair. Recognizing the importance of delivery
strategies in cell-based therapies, decellularized scaffolds have been shown to retain
properties of the native ECM and can instruct cell behaviour to guide tissue regeneration.
With this in mind, the Flynn laboratory is developing DAT scaffolds as a pro-adipogenic
cell delivery platform for ASCs in adipose tissue engineering applications [4]. However,
further investigation of the ASC-mediated regenerative mechanisms would be beneficial
for the development of clinically-translational approaches to enable stable and predictable
adipose tissue regeneration. In particular, the host response is crucial to tissue repair, and
increasingly, studies have demonstrated that macrophages play a central role in this
process. Further, ASCs have been demonstrated to have the capacity to modulate the
macrophage response to implanted biomaterials and may help to promote constructive
tissue remodeling. Therefore, the objective of the current study was to examine donor
ASCs and infiltrating myeloid cells within ASC-seeded and unseeded DAT scaffolds
using transgenic mouse models to facilitate tracking and characterization of these cell
populations.
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Chapter 3

3

Materials and Methods

3.1 Materials
Chemicals and reagents were purchased from Sigma Aldrich (Oakville, ON) unless
otherwise stated.

3.2 Animals
All animal studies were performed in accordance with the Canadian Council on Animal
Care (CCAC) guidelines and were approved by the Animal Care Committee at Western
University (Protocol # 2015-049; Appendix 2). Mice were housed in clean barrier
facilities under humidity- and light-controlled conditions, and fed ad libitum with free
access to water. Murine adipose-derived stem/stromal cells (ASCs) were obtained from
8-12 week old male dsRed mice (B6.Cg-Tg(CAG-DsRed*MST)1Nagy/J; C57BL/6J
background; Jackson Laboratory, Bar Harbor, ME). Scaffold implantation studies were
performed using a total of thirty hemizygous 8-12 week old female MacGreen transgenic
mice (B6N.Cg-Tg(Csf1r-EGFP)1Hume/J; C57BL/6J background; Jackson Laboratory,
Bar Harbor, ME).

3.3 ASC isolation and culture
ASCs were isolated from the inguinal fat pads of dsRed mice according to previously
published methods [308]. Briefly, fat pads from 4-7 mice were minced with sharp
surgical scissors and added to 15 mL of collagenase digest solution consisting of 0.1%
Type I Collagenase (Worthington Biochemical Corp., Lakewood, NJ), 1% bovine serum
albumin (BSA), and 2 mM calcium chloride in cation-free phosphate-buffered saline
(PBS). The tissue suspension was agitated (75 rpm) at 37˚C for 1 hour and then
centrifuged at 300 x g for 5 min to obtain the stromal vascular fraction. The cell pellet
was then re-suspended in PBS + 1% BSA and passed through a 100 µm filter (Corning
Inc., Corning, NY). The cells were centrifuged again (300 x g for 5 min) and resuspended in proliferation medium composed of Dulbecco’s Modified Eagle’s
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Medium:Ham’s F12 (DMEM:Ham’s F12) with 10% fetal bovine serum (FBS; Gibco®,
Invitrogen, Burlington, ON) and 1% penicillin-streptomycin (pen-strep; Gibco®,
Invitrogen, Burlington, ON) prior to plating on PrimariaTM flasks (Corning Inc., Corning,
NY). After 24 h incubation (37˚C, 5% CO2), the flasks were rinsed with sterile PBS to
remove cellular debris and unattached cells, and the proliferation medium was then
replaced. The cells were passaged at confluence using 0.25% trypsin/0.1%
ethylenediaminetetraacetic acid (trypsin/EDTA; Gibco®, Invitrogen, Burlington, ON) and
re-plated at 6,000-7,000 cells/cm2 on standard tissue culture polystyrene flasks (Corning
Inc., Corning, NY) beyond passage zero (P0). Media changes were performed every 2-3
days and P3 cells were used in all studies.

3.4 ASC characterization
3.4.1

Immunophenotyping

Flow cytometry was performed in conjunction with Mrs. Christy Barreira (Research
Assistant, Dekaban laboratory), and Dr. Laura Juignet (Post-doctoral Fellow, Flynn
laboratory). P3 dsRed+ murine ASCs were incubated with 5 mL of 0.48 mM Versene
Solution (Gibco®, Invitrogen, Burlington, ON) for 10 min at 37˚C to detach the cells,
followed by addition of 5 mL of complete media and centrifugation (1200 x g, 5 min).
The cell pellet was re-suspended in PBS supplemented with 5% FBS, and hemocytometer
counts with trypan blue-stained cell suspensions were performed to aliquot 250,000 cells
each in 5 mL polystyrene round-bottom tubes (Falcon®, Corning, NY). After
centrifugation (450 x g, 7 min), the cell pellets were re-suspended in 250 µL of PBS
containing the LIVE/DEAD™ Fixable Aqua Dead Cell Stain (Fisher Scientific, Ottawa,
ON) prepared according to the manufacturer’s instructions. After 30 min of incubation in
the dark at room temperature, cells were pelleted (450 x g, 7 min) and re-suspended in
100 µL of PBS + 5% FBS and the following monoclonal APC-conjugated antibodies
from eBioscience (Ottawa, ON) were added to separate tubes: anti-CD29 (1 µg/mL; cat.
17-0291), anti-CD31 (2 µg/mL; cat. 17-0311), anti-CD44 (0.24 µg/mL; cat. 17-0441),
anti-CD45 (0.5 µg/mL; cat. 17-0451), and anti-CD90.2 (0.24 µg/mL; cat. 17-0902). The
cells were then incubated for 25 min at 4˚C in the dark and centrifuged at 450 x g for 7
min). An additional wash step was performed in PBS, and the cells were then re36

suspended in 200 µL of PBS + 5% FBS. The stained cells were fixed through the addition
of 100 µL of PBS + 0.5% paraformaldehyde, and stored at 4˚C in the dark. Flow
cytometry was performed within 24 h of staining using an LSRII analytical cytometer
(Becton Dickinson) at the London Regional Flow Cytometry Facility. Live singlets were
gated on the basis of the forward and side scatter properties, with further gating
performed using fluorescence minus one (FMO) controls, including wild-type (dsRed-)
P3 murine ASCs isolated from non-transgenic 8-12 week old male C57BL/6J mice that
were cultured in parallel to the dsRed+ cells. Data analysis was performed using FlowJo
software (version 10.0.8; Tree Star, Ashland, OR).

3.4.2

Adipogenic differentiation

ASCs were plated at 50,000 cells/cm2 on 12-well TPP® plates and incubated in
proliferation media for 24 h. The cells were then induced to differentiate using an
adipogenic differentiation medium (Table 3.1) adapted from the literature [308]. Media
was changed every 2-3 days and adipogenic differentiation was characterized through oil
red O staining and measurement of glycerol-3-phosphate dehydrogenase (GPDH)
enzyme activity at 14 days in comparison to non-induced controls maintained in
proliferation medium.
Table 3.1. Summary of differentiation media formulations. All formulations were
prepared in DMEM:Ham’s F12 with 10% FBS and 1% pen-strep. IBMX: 3-isobutyl-1methylxanthine, TGF-β1: transforming growth factor beta-1.
Adipogenic differentiation
Osteogenic differentiation
media [308]
media [105]
10 mg/mL troglitazone*
345 µM ascorbic acid
0.25 mM IBMX*
10 mM β-glycerol phosphate
33 µM biotin
1 µM retinoic acid
17 µM D-pantothenic acid
10 mg/mL human insulin
1 µM dexamethasone
*Included only for the first 72 h of differentiation
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Chondrogenic
differentiation media
50 µg/mL ascorbic acid
100 nM dexamethasone
6.25 µg/mL TGF-β1 (R&D
Systems, cat. 100-B-001)

3.4.2.1

Oil red O staining

Oil red O histological staining was performed as previously described [184] to visualize
intracellular lipid accumulation. Following 30 min fixation at room temperature in 10%
neutral buffered formalin, the cells were rinsed three times with deionized water and
incubated in oil red O working solution (3 parts oil red O stock consisting of 3 g/L oil red
O in 99.9% isopropanol to 2 parts deionized water) for 8 min under gentle agitation. Cells
were then rinsed with deionized water to remove excess stain, and counterstained with
hematoxylin for 2 min. Staining was performed in technical triplicates for each trial and
the experiment was repeated for a total of 4 biological replicates (n=3 induced, 3 noninduced technical replicates, N=4 experiments from separate ASC isolations). The
samples were imaged using the EVOS® XL Core imaging system (Fisher Scientific,
Ottawa, ON).
In order to semi-quantitatively analyze the levels of intracellular lipid accumulation in the
oil red O-stained samples, dye elution was performed after imaging the samples, followed
by spectrophotometric analysis of the extracted dye (n=3, N=3). After thorough rinsing of
the plates with deionized water to remove non-specific background, 350 µL of absolute
isopropanol was added to each well and incubated for 15 min under gentle agitation at
room temperature. Following this, 100 µL of the supernatant was then transferred from
each replicate sample into triplicate wells of a 96-well plate. Absorbance was read at 492
nm using a CLARIOstar® spectrophotometer (BMG LabTech, Ortenberg, Germany).
Wells with isopropanol alone were included to measure the background absorbance
levels. The average absorbance was calculated for each sample, with the background
subtracted.

3.4.2.2

GPDH Enzyme Activity

Quantitative assessment of adipogenic differentiation was performed by measuring the
activity of the lipid biosynthetic enzyme GPDH (N=4, n=3), following previously
described protocols [184]. A commercially available spectrophotometric assay (cat. KT010; Kamiya Biomedical Company, Seattle, WA) was used to measure intracellular
GPDH activity with levels normalized to total cytosolic protein using the Bio-Rad protein
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assay (Bio-Rad Laboratories Inc., Hercules, CA) with an albumin standard. All samples
were measured at an absorbance of 340 nm using a CLARIOstar® spectrophotometer
(BMG LabTech, Ortenberg, Germany). One unit of GPDH activity was defined as the
activity required to oxidize 1 µmole of NADH in 1 minute.

3.4.3

Osteogenic differentiation

For osteogenic differentiation, ASCs were plated at 15,000 cells/cm2 in 12-well plates
pre-coated with laminin (cat. L2020, 1.6 µg/cm2) and incubated in proliferation medium
for 24 h. Differentiation was induced using osteogenic medium (Table 3.1) [105], with
media changes performed every 2-3 days. Osteogenic differentiation was assessed via
von Kossa staining of matrix mineralization, as well as assessment of alkaline
phosphatase (ALP) enzyme activity in comparison to non-induced controls maintained in
proliferation medium.

3.4.3.1

Von Kossa staining

Matrix mineralization was visualized after 28 days of differentiation by von Kossa
staining as described previously (n=2-3, N=3) [309]. The cells were fixed in 10% neutral
buffered formalin for 30 min and rinsed with deionized water. Following this, the plates
were incubated in 1% silver nitrate solution under ultraviolet light for 90 minutes. After
rinsing, 5% sodium thiosulfate solution was added to the wells and incubated for 2 min.
Counterstaining with hematoxylin was performed for 2 min, and the plates were imaged
using the EVOS® XL Core imaging system (Fisher Scientific, Ottawa, ON).

3.4.3.2

ALP enzyme activity

After 7 days of culture in differentiation media, measurement of ALP enzyme activity
was performed as previously described (n=3, N=4) [309]. Extraction of intracellular
protein was performed by sonicating the cells in enzyme extraction buffer (5 mM tris, 20
mM tricine, 1 mM EDTA, pH 7.4), followed by centrifugation (13,000 x g, 10 min) and
collection of the cell supernatant. Next, 100 µL of the extracted sample was incubated
with an equal volume of p-nitrophenyl liquid substrate (cat. N7653) in a 96-well plate for
30 min at 37˚C. The reaction was then quenched with 100 µL of 3 N NaOH and the
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absorbance was measured at 405 nm using a CLARIOstar® spectrophotometer (BMG
LabTech, Ortenberg, Germany). Absorbance values were referenced to a p-nitrophenol
standard curve, with normalization to total intracellular protein using the Bio-Rad protein
assay (Bio-Rad Laboratories Inc., Hercules, CA) with an albumin standard. One unit of
ALP activity was defined as the amount of enzyme required to catalyze the production of
1 µmole of p-nitrophenol per minute.

3.4.4

Chondrogenic differentiation

ASC chondrogenic differentiation was induced in 3D cell aggregate cultures based on
methods previously described [183]. In brief, 1 mL of proliferation medium containing
250,000 ASCs was transferred into a 15 mL vented cap conical tube and centrifuged at
300 x g for 5 min. ASCs were cultured in proliferation medium for 3 days to allow the
cells to self-assemble into 3D aggregates. The medium was then replaced with
chondrogenic medium (Table 3.1), with half media changes performed every second day.
On day 28, the cell pellets were rinsed in PBS and frozen on dry ice in Tissue-Tek®
O.C.T.T.M. Compound (Sakura® Finetek, Torrance, CA). Differentiation was qualitatively
assessed by immunohistochemical staining for collagen I and II relative to non-induced
controls maintained in proliferation medium (n=3, N=3).

3.4.4.1

Immunohistochemical staining for collagen I and II

The cell aggregates were cryosectioned (5-7 µm) and stored at -80˚C. Prior to staining,
the sections were washed with PBS, followed by blocking for 1 h at room temperature in
PBS containing 10% goat serum and 0.2% Tween-20. The sections were then incubated
with primary antibodies to collagen I (1:200 dilution; cat. ab34710; Abcam, Toronto,
ON) or collagen II (1:200 dilution; cat. ab34712; Abcam, Toronto, ON) overnight at 4˚C.
After washing with PBS, a goat anti-rabbit secondary antibody (1:500; cat. ab96902;
Abcam, Toronto, ON) was then applied to the tissue sections for 1 h at room temperature.
The sections were then washed, followed by mounting using DAPI mounting medium
(Abcam, Toronto, ON) and imaging with the EVOS® FL Imaging System. Tissuepositive porcine auricular cartilage samples and no primary controls were used to confirm
staining specificity.
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3.5 DAT scaffold fabrication and seeding
3.5.1

Adipose tissue procurement and decellularization

Subcutaneous human adipose tissue was obtained with informed consent from elective
breast reduction or abdominoplasty surgeries at Cumberland Laser Clinic, St. Joseph’s
Hospital, or University Hospital in London, Ontario with approval from the Research
Ethics Board at Western University (HREB# 105426; Appendix 2). The tissues were
transported to the lab on ice in sterile PBS supplemented with 20 mg/mL BSA, and
processed within 2 hours of excision. Cauterized tissue was removed and the remaining
sample was transferred into hypotonic 10 mM Tris-EDTA buffer (pH 8.0), and frozen at 80˚C. Tissue decellularization was performed using an established 5-day detergent-free
protocol [5]. A working volume of 100 mL solution/50 g of tissue was used for all
decellularization solutions. The solutions were supplemented with 1% (v/v) antibioticantimycotic (ABAM; Gibco®, Invitrogen, Burlington, ON) and 0.27 mM
phenylmethylsulfonyl fluoride (PMSF), with the exception of steps including 0.25%
trypsin/0.1% EDTA where PMSF was excluded. All incubations were performed at 37˚C
under constant agitation at 120 rpm.
In brief, the adipose tissue samples were thawed at 37˚C under agitation, and the tissue
was placed in fresh 10 mM Tris-EDTA buffer. The samples were then frozen at -80˚C
and this processing step was repeated for a total of three freeze-thaw cycles. After the
final freeze-thaw, the tissue was subjected to enzymatic digestion in 0.25% trypsin/0.1%
EDTA (Gibco®, Invitrogen, Burlington, ON) overnight. Polar solvent extraction was then
performed by transferring the samples into absolute isopropanol for a total of 48 h, with
gentle mechanical manipulation and solution changes to promote lipid extraction every 8
h. The samples were then rinsed three times (30 min each) in Sorenson’s phosphate
buffer (SPB) rinsing solution (8 g/L NaCl, 200 mg/L KCl, 1 g/L Na2HPO4, and 200 mg/L
KH2PO4, at pH 8.0), and incubated in 0.25% trypsin/0.1% EDTA for 6 h. Following three
additional 30 min washes in SPB rinsing solution, the samples were transferred to a
second enzymatic digestion solution (55 mM Na2HPO4, and 17 mM KH2PO4, 4.9 mM
MgSO4•7H2O) containing 15,000 U DNase Type II (from bovine pancreas), 12 mg
RNase Type III A (from bovine pancreas), and 2000 U lipase Type VI-S (from porcine
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pancreas). Three 30 min washes were then performed in SPB rinsing solution prior to
incubation in absolute isopropanol for 8 h, followed by an additional three 30 min rinses
in the same rinsing solution. The decellularized adipose tissue (DAT) was then frozen at 80˚C and lyophilized.

3.5.2

Scaffold preparation and seeding

Lyophilized DAT was cut into (7.0 ± 0.5) mg scaffolds and re-hydrated in deionized
water overnight. Three 30 min washes in 70% ethanol were performed, followed by
overnight incubation in 70% ethanol to decontaminate the scaffolds. The scaffolds were
then transferred under aseptic conditions into sterile PBS and incubated for 3 h at room
temperature, followed by an additional two 30 min rinses in fresh sterile PBS. The PBS
was then replaced with ASC proliferation medium (89% DMEM:Ham’s F12, 10% FBS,
1% pen-strep) and the scaffolds were incubated overnight at 37 ˚C and 5% CO2.
Prior to scaffold seeding, P2 ASCs were trypsinized and counted using a hemocytometer.
Each DAT scaffold was transferred into a 15 mL vented cap conical tube containing 3
mL of proliferation medium and 2 x 106 ASCs. The scaffolds were dynamically seeded
for 24 h using a BenchWaverTM 3D rocker (Mandel, Guelph, ON) at 90 rpm (37 ˚C, 5%
CO2).
For the initial seeding pilot studies, three different seeding densities were examined: 0.5 x
106 ASCs/scaffold, 1.0 x 106 ASCs/scaffold, and 2.0 x 106 ASCs/scaffold (n=3 technical
replicates; N=2 experiments with separate batches of isolated ASCs). After 24 h of
seeding, the scaffolds were frozen over dry ice in Tissue-Tek® O.C.T.T.M. Compound
(Sakura® Finetek, Torrance, CA). The scaffolds were then stored at -80˚C for subsequent
sectioning (5-7 µm sections) and mounting with DAPI mounting medium (Abcam,
Toronto, ON) in order to visualize cells. Images were taken using the EVOS® FL
Imaging System (Invitrogen, Ottawa, ON). All subsequent studies were performed using
a seeding density of 2 x 106 ASCs/scaffold.
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3.6 Scaffold implantation, tissue harvest, and Masson’s
trichrome staining
As stated previously, implantation studies were performed using 8-12 week old female
MacGreen transgenic mice. All surgeries were performed under sterile conditions using
sterile surgical tools. Animals were anesthetized with 1.5% isoflurane in oxygen at 1
L/min throughout the surgical procedure, and administered subcutaneous injections of
meloxicam (2 mg/kg loading dose; 1 mg/kg follow up dose at 24 h) as an analgesic, as
well as bupivacaine (2 mg/kg) as a local anaesthetic. Two small incisions (~1 cm) were
made on the dorsa of each mouse below each scapula, and subcutaneous pockets were
created below the panniculus carnosus using blunt-ended forceps. One ASC-seeded and
one unseeded DAT scaffold were placed into the separate pockets created in each mouse
and the incisions were closed using 11 mm Michel wound clips (Fig. 3.1A).
At time points of 72 h, 1, 3, 5, and 8 weeks post-implantation, cohorts (n=6 mice per time
point) were euthanized by isoflurane overdose and the scaffolds were excised within their
surrounding tissues (Fig. 3.1B). The excised scaffolds were bisected using a scalpel and
half of each implant was fixed in 10% neutral buffered formalin for 24 h prior to being
transferred to 70% ethanol for paraffin-embedding. The remaining half of each scaffold
was frozen over dry ice in Tissue-Tek® O.C.T.T.M. Compound (Sakura® Finetek,
Torrance, CA) for immunohistochemical analysis.
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Figure 3.1. Scaffold implantation and excision. A) Each mouse was implanted with
one seeded and one unseeded scaffold inserted into separate subcutaneous pockets on the
dorsa below each scapula. Incisions were closed with surgical staples. B) The basal
surface of an excised DAT scaffold. Dotted line delineates scaffold region; scale bar: 0.5
cm.

3.6.1

Masson’s trichrome staining

Sections of 5-8 µm thickness from paraffin-embedded tissues were deparaffinized in
xylene, and rehydrated in a graded ethanol series prior to Masson’s trichrome staining.
The tissue sections were then dehydrated in a graded ethanol series and mounted with
Permount® (Fisher Scientific, Ottawa, ON). Slides were scanned at 20X magnification
using an Aperio ImageScope system and software (Vista, CA). The fraction of the
implants infiltrated by cells or remodeled into adipose tissue was quantified relative to
the total implant area using the Spectrum ImageScope software.

3.7 Immunohistochemical detection of dsRed+ donor cells
For dsRed staining, 5 µm sections from paraffin-embedded tissues were deparaffinized
and re-hydrated in a graded ethanol series, followed by heat-mediated antigen retrieval in
citrate solution (pH 6.0) at 95˚C for 30 min. This was followed by blocking (10% goat
serum + 0.1% Tween-20 in Tris-buffered saline (TBS)) for 1 h at room temperature. The
tissue sections were then incubated overnight at 4˚C with a rabbit polyclonal anti-RFP
primary antibody (1:200 in TBS + 5% goat serum + 0.1 % Tween-20, cat. 600-401-379;
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Rockland Immunochemicals, Limerick, PA). Following this, the tissue sections were
washed in TBS, and endogenous peroxidases were quenched in 3% H2O2 for 15 min at
room temperature. After applying a goat anti-rabbit HRP-conjugated secondary antibody
(1:300 in TBS, Abcam cat. Ab6721), sections were washed in TBS and incubated with
3,3′-diaminobenzidine (DAB) for 5 min at room temperature followed by counterstaining with Harris hematoxylin and lithium carbonate, dehydration in a graded ethanol
series, and mounting with Permount® (Fisher Scientific, Ottawa, ON). Slides were
scanned at 20X magnification using an Aperio ImageScope system and software (Vista,
CA), and quantitative analysis of positively stained pixels was performed using the Fiji
software [310]. DAT scaffolds implanted into dsRed+ mice and wild-type mice were used
as positive and negative controls respectively, along with no primary controls to confirm
staining specificity.

3.8 In vivo optical imaging
Optical imaging studies were performed in collaboration with Dr. John Ronald
(Department of Medical Biophysics, Western University) with technical assistance from
Ms. Katie Parkins (PhD Candidate, Ronald laboratory) using the IVIS® Lumina XRMS
In Vivo imaging system (PerkinElmer, Waltham, MA). In an initial pilot study, DAT
scaffolds were seeded with dsRed+ donor ASCs or EGFP+ macrophages derived from
MacGreen mice isolated and cultured by Mr. Hisham Kamoun (MESc Candidate, Flynn
lab). Scaffolds were seeded using the methods outlined in Section 3.5.2; for ASCseeding, densities of 0.5 x 106 ASCs/scaffold, 1.0 x 106 ASCs/scaffold, and 2.0 x 106
ASCs/scaffold were used, and for macrophage-seeding, densities of 0.25 x 106
ASCs/scaffold, 0.5 x 106 ASCs/scaffold, and 1.0 x 106 ASCs/scaffold were used, with
unseeded controls included to assess levels of autofluorescence in the DAT (n=3
technical replicates/seeding density). These seeding densities were selected based on
previously noted differences between these cell populations in terms of cell attachment to
the DAT scaffolds. The total radiant efficiency for either dsRed or EGFP fluorescence
was measured within the different seeded scaffolds using region-of-interest (ROI)
analysis in the Living Image® 4.5.2 Software (PerkinElmer, Waltham, MA).
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Subsequent in vivo studies were performed to track dsRed+ donor ASCs within the
implants in living mice. A longitudinal study was performed with eight mice (N=8)
imaged at a baseline of 24 h pre-implantation, as well as at 24 h, 1, 3, 5, and 8 weeks
post-implantation. At 24 h prior to each imaging time point, the hair on the dorsal region
in the implant area was removed with shaving and NairTM hair removal cream. At all time
points, the mice were anesthetized using 2% isoflurane in oxygen at 1 L/min and the
lateral surface of each animal was imaged. The total radiant efficiency was measured
within the region of the implanted scaffolds using ROI analysis in the same software
described above. At some time points, darkening of the skin within the implant region
was noted, due to changes in the hair growth cycle over time. This appeared to greatly
interfere with signaling acquisition for some mice, and as a result, these mice were
excluded such that data from 3-8 mice was collected at each of the time points.

3.9 Immunohistochemical assessment of macrophage
infiltration and macrophage phenotypic markers
To examine infiltrating macrophages, immunohistochemical staining was performed
using the specifications outlined in Table 3.1. Co-staining was performed for the
following combinations of markers: EGFP with Iba1, EGFP with arginase-1 (Arg-1), and
EGFP with inducible nitric oxide synthase (iNOS). Five micron sections from freshfrozen tissues were fixed in acetone at -20˚C for 10 min. After washing in TBS, the
sections were blocked for 1 h at room temperature. The primary antibody for Iba1, iNOS,
or Arg-1 was then applied at a dilution of 1:100 in the blocking solution and incubated
overnight at 4˚C. The tissue sections were then washed in TBS and the secondary
antibody was applied at a dilution of 1:500 in TBS for 30 min at room temperature.
EGFP staining was then performed using the same procedures, but with no secondary
antibody required since the primary antibody used was directly conjugated to the Alexa
Fluor 647 fluorophore. After the EGFP antibody incubation, the tissue sections were
washed and stained with Hoescht (Fisher Scientific, Ottawa, ON) followed by mounting
with FluoroshieldTM Mounting Medium (Abcam, Toronto, ON). For EGFP/Iba1 costaining, blinded quantitative analysis was performed in ImageJ through manual counting
of DAPI+ cells positive for both markers and cells positive only for EGFP. Average
46

counts from 5-6 20X images taken along the implant periphery (2-3 along the basal
border, 2-3 along the apical border) were recorded for each section. EGFP/iNOS and
EGFP/Arginase-1 co-staining was performed on adjacent sections and assessed
qualitatively. All images were taken at 20X magnification with the EVOS® FL Imaging
System (Invitrogen, Ottawa, ON). Tissue-positive mouse spleen controls and no primary
controls were used to confirm staining specificity for each of these markers.
Table 3.2. Specifications for immunohistochemistry protocols.
EGFP
Blocking
TBS + 10% rabbit
solution
serum + 0.1%
tween-20
Primary
Rabbit polyclonal,
antibody
Alexa 647
(cat. A-31852a)
Secondary
antibody

Iba1
iNOS
Arg-1
TBS + 10% goat TBS + 5% BSA + TBS + 5% BSA +
serum + 0.1%
0.1% tween-20
0.1% tween-20
tween-20
Rabbit
Rabbit polyclonal
Chicken
b
monoclonal (cat.
(cat. ab15323 )
polyclonal (cat.
b
ab178846 )
ABS535c)
Goat anti-rabbit,
Goat anti-rabbit, Goat anti-chicken,
Alexa 594
Alexa 594
Alexa 568
b
b
(cat. ab150080 )
(cat. ab150080 )
(cat. A11041a)
a
Fisher Scientific, Ottawa, ON; bAbcam, Toronto, ON; cMillipore, Etobicoke, ON

3.10 Statistical Analysis
Data were analyzed using GraphPad Prism 6.0 software (GraphPad Software, San Diego,
CA) and are reported as the mean ± standard deviation. Differences were considered
statistically significant at p<0.05. Grubb’s test was used to identify statistical outliers.
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Chapter 4

4

Results

4.1 ASC characterization
4.1.1

Cell surface marker expression

Immunophenotyping of dsRed+ murine adipose-derived stem/stromal cells (ASCs) at
passage 3 (P3) showed cell surface marker expression consistent with previous findings
[106, 311]. Analysis of the viable cell population demonstrated that the ASCs were
positive for the stromal cell markers CD29 (99.3 ± 0.8%), CD44 (99.0 ± 0.8%), and
CD90 (98.6 ± 0.9%). Further, the cells were negative for the endothelial cell marker
CD31 (0.1 ± 0.1%) and the hematopoietic pan-leukocyte marker CD45 (0.6 ± 0.3%)
(N=3 separate ASC isolations; Figure 4.1, fluorescence minus one (FMO) controls shown
in Supplementary Figure 1).
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Figure 4.1. dsRed+ mouse ASCs express characteristic cell surface markers. A) Cells
were gated based on their forward scatter (FSC) and side scatter (SSC) distribution
(82.6%) followed by selection of FSC singlets (99.3%), and selection of the viable cell
population (83.0%). B) Representative scatter plots from one biological replicate
demonstrating dsRed+ cell expression of CD29 (100% positive), CD44 (99.5% positive),
and CD90 (99.6% positive). Mean ± standard deviation from N=3 separate experiments
displayed above each plot. C) dsRed+ cells were negative for CD45 (0.2% positive) and
CD31 (0.4% positive). Mean ± standard deviation from N=3 separate experiments
displayed above each plot.
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4.1.2

Trilineage differentiation

To verify that the ASCs used in these studies displayed multipotent differentiation
potential, the capacity of the cells to differentiate in culture toward the adipogenic,
osteogenic, and chondrogenic lineages was confirmed.
ASCs cultured under adipogenic conditions exhibited intracellular lipid accumulation
characteristic of developing adipocytes after 14 days of culture, whereas non-induced
controls showed minimal lipid droplet formation as assessed by qualitative oil red O
staining (n=3 induced, 3 non-induced wells, N=3 experiments from different ASC
isolations; Figure 4.2A). Quantitative absorbance measurements of the dye eluted from
oil red O-stained plates by spectrophotometry showed significantly greater levels of
staining in induced relative to non-induced controls (Figure 4.2B). In addition,
significantly enhanced activity of the enzyme glycerol 3-phosphate dehydrogenase
(GPDH) involved in lipid biosynthesis was observed relative to non-induced controls
after 14 days of culture (n=3, N=4; Figure 4.2C).

50

Figure 4.2. ASCs differentiate toward the adipogenic lineage. A) ASCs induced
toward the adipogenic lineage displayed enhanced intracellular lipid accumulation (red
stain) relative to non-induced controls after 14 days of culture (n=3, N=3). 4X scale:
1000 µm, 10X scale: 500 µm. B) Absorbance measurements of dye eluted from oil red
O-stained plates revealed increased oil red O staining in induced cultures by
spectrophotometry (n=3, N=3). C) Greater GPDH enzyme activity was observed in
induced cell cultures at 14 days (n=3, N=4). Student’s t-test. ***p<0.001.

In cells grown under osteogenic conditions, induced cells displayed significantly higher
activity levels of the enzyme alkaline phosphatase (ALP) – an early marker of
osteogenesis involved in the mineralization process – relative to non-induced controls
(n=3, N=4; Figure 4.3A). After 28 days of culture, small mineral deposits could be
visualized by von Kossa staining within induced cells, but not in non-induced controls
(n=2-3, N=3; Figure 4.3B).
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Figure 4.3. ASCs differentiate toward the osteogenic lineage. A) Increased ALP
enzyme activity was observed after 7 days in culture in induced cells relative to noninduced controls (n=3, N=4). B) Mineralization (arrows) was detected in ASCs cultured
under osteogenic conditions for 28 days (n=2-3, N=3; scale: 200 µm). Student’s t-test.
*p<0.05.

Lastly, to assess chondrogenic differentiation, collagen I and II expression was
qualitatively evaluated by immunohistochemistry within 3D cell aggregates. Collagen II
is the predominant form of collagen found in the extracellular matrix (ECM) of healthy
articular cartilage and the chondrogenic differentiation of mesenchymal stem/stromal
cells (MSCs) is associated with a shift from collagen I to collagen II expression [312]. A
qualitatively higher collagen II to collagen I ratio was observed within induced cell
aggregates compared to non-induced controls suggestive of chondrogenic differentiation
(n=2-4, N=3; Figure 4.4, staining controls shown in Supplementary Figure 2).
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Figure 4.4. ASCs differentiate toward the chondrogenic lineage. Induced cell
aggregates displayed a qualitatively higher ratio of collagen II to collagen I expression
compared to non-induced controls after 28 days of culture. n=2-4, N=3. Green: positive
staining for collagen I or II (as indicated), blue: cell nuclei. Scale: 200 µm.

4.2 ASC seeding and attachment to DAT scaffolds
Initial pilot studies were performed in order to verify the attachment of ASCs to the DAT
scaffolds with dynamic seeding on a 3D rocker for 24 h. Staining results confirmed cell
attachment for each of the three seeding densities examined (0.5x106 ASCs/scaffold,
1x106 ASCs/scaffold, 2x106 ASCs/scaffold; n=3 technical replicates, N=2 separate
batches of ASC isolations; Figure 4.5). The majority of attached cells were observed
along the scaffold periphery, with fewer cells distributed heterogeneously toward the
interior. Qualitative comparisons showed greater numbers of attached cells in the
scaffolds seeded at the higher densities. A seeding density of 2x106 ASCs/DAT scaffold
was selected for all subsequent in vivo experiments, as there was a more homogeneous
distribution of ASCs along the scaffold periphery in this group.
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Figure 4.5. ASCs attach to DAT scaffolds under in vitro dynamic seeding conditions.
Representative images along the scaffold periphery of DAT scaffolds seeded at three
different cell densities (0.5x106 ASCs/scaffold, 1x106 ASCs/scaffold, 2x106
ASCs/scaffold) demonstrate ASC attachment. Insets in 4X images (left panels) are
magnified at 10X (right panels). Dotted line: scaffold periphery. Blue: cell nuclei, green:
scaffold autofluorescence. 4X scale: 500 µm, 10X scale: 250 µm. n=3, N=2.
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4.3 Cell recruitment and tissue remodeling within implanted
DAT scaffolds
ASC-seeded and unseeded DAT scaffolds were well tolerated after subcutaneous
implantation into MacGreen mice. The incision sites healed within the course of the first
week and there were no detectable signs of inflammation or irritation in any of the
animals. Macroscopically, the implants appeared to retain their shape and volume over
the course of the 8 week period.
Masson’s trichrome stained sections of ASC-seeded and unseeded DAT implants were
used to qualitatively assess cell recruitment, angiogenesis, and adipogenesis at 72 h, 1, 3,
5, and 8 weeks post-implantation. Follow-up quantitative analysis of cell infiltration and
adipogenesis was performed to examine differences between the seeded and unseeded
scaffold groups.

4.3.1

Qualitative assessment of cell infiltration and tissue
remodeling

In Masson’s trichrome stained sections, a thin fibrous capsule was visualized along the
scaffold periphery starting at the 1 week time point, persisting over the course of the
study. All adipocytes and blood vessels contained within this fibrous capsule were
considered newly formed tissues. Within the seeded implants, the DAT appeared to be
denser and slightly contracted at the 8 week time point relative to the unseeded implants
in which the scaffold shape and structure appeared to be relatively consistent over time.
Qualitatively, there appeared to be increased cell recruitment within the ASC-seeded
implants at the later time points relative to 72 h (Figure 4.6). In contrast, low levels of
cell infiltration were observed in the unseeded DAT controls (Figure 4.7). Erythrocytecontaining blood vessels were detected in both the ASC-seeded and unseeded DAT
scaffolds along the implant periphery. Qualitatively, greater numbers of vessels were
visualized in the seeded versus unseeded scaffolds as early as 1 week post-implantation.
Newly formed adipose tissue was also observed within the seeded and unseeded scaffold
groups, and was predominantly localized along the apical border; however, in a small
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fraction of the implants, mature adipocytes were also observed on the lateral surfaces
toward the periphery.
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Figure 4.6. ASC-seeded DAT scaffolds enhance cell recruitment, adipogenesis, and
angiogenesis. Representative images of seeded DAT implants excised at each time point
are shown. Insets in left panels are magnified in right panels. Dotted line: scaffold
periphery; arrows: adipocytes; arrow heads: erythrocyte-containing blood vessels. Left
panels scale: 1 mm, right panels scale: 200 µm.
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Figure 4.7. Low levels of cell recruitment, adipogenesis, and angiogenesis were
observed in unseeded DAT scaffolds. Representative images of unseeded DAT
implants excised at each time point are shown. Insets in left panels are magnified in right
panels. Dotted line: scaffold periphery; arrows: adipocytes; arrow heads: erythrocytecontaining blood vessels. Left panels scale: 1 mm, right panels scale: 200 µm.
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4.3.2

Cell recruitment

Measurement of the degree of cell infiltration in ASC-seeded and unseeded implants was
performed on Masson’s trichrome stained sections (Figure 4.8A). Within seeded
scaffolds, there was significantly greater cell recruitment at 1 and 5 weeks compared to
72 h post-implantation (N=5-6 implants/treatment group/time point; Figure 4.8B). At 8
weeks post-implantation, cell recruitment within the seeded scaffold group was
significantly greater compared to the previous time points, and was significantly different
from the unseeded controls. Within the unseeded scaffolds, there was increased cell
infiltration at 8 weeks post-implantation relative to the unseeded controls at 72 h.
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Figure 4.8. ASC-seeding enhances cell recruitment within DAT scaffolds. A) Sample
implant cross-section illustrating the DAT scaffold region (contained within the area
outlined by the green line) and the area of the scaffold infiltrated by cells (area between
green and yellow lines). Scale bar: 1 mm. B) Quantitative measurements of the
percentage area of cell infiltration revealed increased cell recruitment in the ASC-seeded
scaffolds, with a delayed increase observed within the unseeded group. Two-way
ANOVA, Tukey’s post-hoc. ***p<0.001 between groups indicated, ap<0.05 vs 72 h
seeded, bp<0.0001 vs 72 h seeded, cp<0.001 vs 1 wk and 3 wks seeded, dp<0.01 vs 5 wks
seeded, ep<0.05 vs 72 h and 1 wk unseeded. N=5-6 implants/treatment group/time point.

4.3.3

Adipose tissue remodeling

Within Masson’s trichrome stained tissue sections, quantitative analysis of adipose tissue
remodeling revealed that a small amount of adipose tissue (<1% of the implant area)
could be detected within the implant region as early as 1 week post-implantation (Table
4.1). Adipocytes were detected in a greater number of the ASC-seeded implants
compared to unseeded controls at 1, 3, 5, and 8 weeks post-implantation. Moreover,
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larger areas of remodeled adipose tissue were observed within the seeded group at the 3,
5, and 8 week time points compared to unseeded controls.
Table 4.1. Adipose tissue remodeling in ASC-seeded and unseeded DAT implants.
The number of implants containing adipocytes is displayed as a fraction of the total
implants analyzed within each treatment group and time point. For groups in which
adipocytes were observed, histological scoring of the percentage area of adipose tissue
remodeling was performed and is indicated as a range by the number of ‘+’ symbols
within brackets. +<1% adipose tissue, ++1-5%, +++5-10%.
Seeded

Unseeded

72 h

0/6

0/6

1 week

4/6 (+)

1/6 (+)

3 weeks

2/6 (++ to +++)

0/6

5 weeks

2/6 (+ to +++)

0/5

8 weeks

4/6 (+ to +++)

3/6 (+)

4.4 Histological detection and optical tracking of syngeneic
donor dsRed+ ASCs within implanted DAT scaffolds
In order to identify dsRed+ donor cells within the implants, immunohistochemical
analysis for dsRed was performed at 72 h, 1, 3, 5, and 8 weeks post-implantation. In
addition, a trial was performed to investigate the feasibility of applying optical imaging
techniques to quantitatively track the dsRed+ ASCs within the implant region in living
mice over time.

4.4.1

Immunohistochemical detection of donor dsRed+ cells

To assess dsRed+ cell retention within the implants, immunohistochemical staining for
dsRed was performed within ASC-seeded implants and unseeded controls, with followup quantitative analysis (N=4-6 implants/treatment group/time point). Positive staining
for dsRed was detected within ASC-seeded implants at all time points examined (Figure
4.9, staining controls shown in Supplementary Figure 3), indicating that the syngeneic
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donor cells were retained over the course of the study. The majority of positive staining
appeared along the scaffold periphery; however, at 5 and 8 weeks post-implantation, a
thin layer of infiltrating host cells was observed peripheral to the dsRed+ cells within the
scaffold. In implants in which adipose tissue formation was observed, the dsRed staining
did not appear in association with the newly formed adipocytes, indicating that the tissues
were host-derived. As expected, no positive staining for dsRed was observed within the
unseeded scaffold controls at any of the time points examined (Figure 4.10).
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Figure 4.9. Syngeneic dsRed+ donor cells are observed in ASC-seeded DAT scaffolds
up to 8 weeks post-implantation and are not localized to newly formed adipocytes.
dsRed+ cells were visualized through DAB staining along the scaffold periphery at each
of the time points examined. Positive staining did not appear in association with
adipocytes formed within the implant region. Insets in left panels are magnified in right
panels. Dotted line: scaffold periphery; arrows: adipocytes within implant region; brown:
positive staining for dsRed. Left panels scale: 1 mm, right panels scale: 200 µm.
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Figure 4.10. dsRed+ cells are not observed in unseeded DAT implant controls. Insets
in left panels are magnified in right panels. Dotted line: scaffold periphery; arrows:
adipocytes within implant region; Brown: positive staining for dsRed. Left panels scale: 1
mm, right panels scale: 200 µm.
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Quantitative analysis of the fraction of dsRed+ stained areas relative to the total implant
area confirmed positive dsRed staining in the majority of the ASC-seeded implants
(Figure 4.11). In contrast, there was no detectable staining for dsRed within the unseeded
DAT controls. No significant differences were observed in terms of the percentage of
positively stained area for dsRed within the ASC-seeded implants over time, supporting
that the syngeneic donor ASCs were retained through the duration of the study.
Variability in the percentage of positively stained areas was noted particularly at the 72 h
and 3 week time points. This may be due to variations in the initial attachment of the
ASCs to the DAT, or potentially due to cell migration or cell death in some cases.

Figure 4.11. Quantitative analysis of immunohistochemical staining confirmed
positive dsRed staining within the ASC-seeded but not unseeded implants.
Measurement of the percentage of area positively stained for dsRed confirmed positive
staining in the ASC-seeded implants, with no significant changes in the percentage of
positively stained area over time. In contrast, there was no detectable dsRed staining
within the unseeded scaffold (not shown). One-way ANOVA, Tukey’s post-hoc test. n.s.:
non-significant.

4.4.2

In vitro fluorescent detection of transgenic ASCs and
macrophages seeded onto DAT scaffolds

To assess the feasibility of applying an optical imaging strategy to track donor dsRed+
ASCs and infiltrating enhanced green fluorescent protein-positive (EGFP+) myeloid cells
in the implants in situ within living animals, a pilot in vitro study was performed using
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DAT scaffolds seeded with these transgenic cell populations (n=3 technical replicates,
N=1 experiment). In scaffolds seeded with dsRed+ ASCs at three different densities
(2.0x106 cells/scaffold, 1.0x106 cells/scaffold, 0.5x106 cells/scaffold), greater levels of
dsRed fluorescence were observed at higher seeding densities (Figure 4.12A).
Quantitative analysis of the radiant efficiency for dsRed confirmed higher levels of
fluorescence in scaffolds seeded at 2x106 cells/scaffold relative to the other groups, with
a decrease in the levels of fluorescence observed at the lower seeding densities (Figure
4.12B). The levels of dsRed fluorescence were greater within each of the seeded
scaffolds compared to the unseeded controls even at the lowest seeding density
examined.
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Figure 4.12. dsRed+ ASCs seeded onto DAT scaffolds in vitro can be detected by
optical imaging. A) Differences in dsRed fluorescence were observed between DAT
scaffold groups seeded with variable numbers of murine dsRed+ ASCs (2x106
ASCs/scaffold, 1x106 ASCs/scaffold, 0.5x106 ASCs/scaffold, or unseeded controls). B)
Quantification of radiant efficiency revealed a decrease in fluorescence at lower seeding
densities. C,D) No differences in GFP fluorescence or radiant efficiency were detected in
DAT scaffolds seeded with variable numbers of EGFP+ macrophages relative to the
unseeded controls.
In contrast to the dsRed+ ASCs, no differences in fluorescence were observed in scaffolds
seeded with EGFP+ macrophages derived from MacGreen mice relative to the unseeded
controls (Figure 4.12C,D). Collagen is highly abundant in the DAT [21] and is known to
autofluoresce at wavelengths that excite GFP [313], which may have interfered with the
ability to detect the macrophages on the scaffolds. Thus, in vivo optical imaging was
performed to track donor dsRed+ ASCs but not infiltrating EGFP+ myeloid cells in
subsequent animal experiments using the MacGreen mouse model.
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4.4.3

In vivo tracking of dsRed+ donor cells

A longitudinal in vivo optical imaging study was performed to track dsRed+ donor cells in
mice implanted with ASC-seeded and unseeded scaffolds. These results showed
increased dsRed fluorescence in seeded versus unseeded scaffolds at 24 h, 72 h, 3, and 5
weeks post-implantation (N=3-8 mice imaged/time point; Figure 4.13A,B). In addition,
dsRed fluorescence was significantly increased in the implant region of seeded scaffolds
at 24 h, 72 h, 3, and 5 weeks post-implantation compared to baseline measurements taken
of the skin at 24 h prior to implantation. At 1 and 8 weeks post-implantation, there was a
significant decrease in dsRed fluorescence within the seeded implant regions of the mice
relative to the 24 h and 72 h time points. Moreover, there were no statistical differences
between the seeded implants at 1 and 8 weeks relative to the unseeded controls at the
same time point, or relative to baseline measurements. This finding appears to contradict
the immunohistochemical analysis of dsRed+ cells within the implants, as dsRed+ cells
were noted at both of these time points. These differences may be attributed to darkening
of the skin with changes in the hair growth cycle that were observed over time, which
may have interfered with signaling acquisition. At the 8 week time point, histological
analysis demonstrated that the seeded DAT implants appeared to be more contracted, and
dsRed+ cells were noted slightly more toward the interior of the scaffold, factors which
may also have contributed to the decrease in dsRed fluorescence. Within the unseeded
implant regions, there were no significant differences between time points or compared to
baseline measurements, consistent with the immunohistochemical data.
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Figure 4.13. Donor dsRed+ cells are detected through optical imaging of ASC-seeded
implant regions of mice at 24 h, 72 h, 3, and 5 weeks post-implantation. A) dsRed
fluorescence was observed within the implant region of the ASC-seeded DAT scaffold
(left panel) but not the unseeded scaffold (right) of a mouse at 24 h post-implantation.
Blue circle delineates implant region. B) Quantification of dsRed radiant efficiency
revealed increased signal in seeded versus unseeded implants at 24 h, 72 h, 3, and 5
weeks, along with significantly higher levels of fluorescence relative to baseline at 24 h
pre-implantation. A decrease in the signal within the seeded implant regions was
observed at 1 and 8 weeks post-implantation relative to 24 h and 72 h, and was not
significantly different from the unseeded controls or baseline controls at these time
points. n=3-8 mice imaged/time point. *p<0.05 between groups indicated, ****p<0.0001,
a

p<0.01 vs 24 h pre-implantation, bp<0.01 vs 24 h post-implantation, cp<0.05 vs 72 h

post-implantation. Two-way ANOVA, Tukey’s post-hoc.
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4.5 Immunohistochemical analysis of infiltrating myeloid
cells
4.5.1

Iba1+ myeloid cell infiltration in DAT implants

In order to investigate immune cell infiltration into the implants, immunohistochemistry
for Iba1, a marker expressed by monocytes and macrophages [314, 315], was performed
in conjunction with staining for EGFP expressed by myeloid cells within the MacGreen
mouse model [25]. EGFP+Iba1+DAPI+ cells were observed in both seeded and unseeded
implants at all time points examined, with peak levels observed at 3 weeks postimplantation within both groups (Figures 4.14 and 4.15; staining controls shown in
Supplementary Figures 4 and 5). Follow-up quantitative analysis was performed to
further assess differences.
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Figure 4.14. Representative images of the scaffold periphery of EGFP and Iba1 costaining in ASC-seeded DAT implants. EGFP+Iba1+DAPI+ cells were observed at 1, 3,
5, and 8 weeks post-implantation with peak infiltration at 3 weeks. Dotted line: scaffold
periphery. Blue: cell nuclei, green: EGFP, red: Iba1. Scale: 100 µm.
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Figure 4.15. Representative images of the scaffold periphery of EGFP and Iba1 costaining in unseeded DAT implants. EGFP+Iba1+DAPI+ cells were observed at 1, 3, 5,
and 8 weeks post-implantation with peak infiltration at 3 weeks. Dotted line: scaffold
periphery. Blue: cell nuclei, green: EGFP, red: Iba1. Scale: 100 µm.
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Quantitative analysis of the EGFP and Iba1 staining was done by manual cell counting
(Figure 4.16; N=5-6 implants/treatment group/time point; n=5-6 20X frames along the
apical and basal borders of the scaffold). The analysis was performed using images
captured on the implant periphery in order to control for the variable degrees of cell
infiltration toward the scaffold interior, which was dependent on the implant group and
the time point examined.
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Figure 4.16. Quantitative analysis of EGFP and Iba1 co-staining along the implant
periphery. A) Counting of DAPI+ cell nuclei revealed a peak cell density within ASCseeded implants (represented by blue circles) at 3 weeks relative to the unseeded controls
(black squares) and the other time points. B) Numbers of EGFP+Iba1+DAPI+ cells peaked
within ASC-seeded implants (blue circles) at 3 weeks relative to the unseeded controls
(black squares) and the other time points. C) Numbers of EGFP+Iba1-DAPI+ cells
gradually declined within ASC-seeded implants (blue circles), becoming significant at 8
weeks relative to 1 week. EGFP+Iba1-DAPI+ cells persisted within unseeded scaffolds
(black squares) up to 3 weeks followed by a significant decline at 5 and 8 weeks. D) The
relative fraction of EGFP+Iba1+DAPI+ cells (solid-filled bars) and total EGFP+ myeloid
cells (stacked column of solid-filled and unfilled bars) was significantly increased within
both seeded and unseeded implants at 3 weeks relative to the other time points examined.
Two-way ANOVA, Tukey’s post-hoc test. *p<0.05 between groups indicated, **p<0.01,
***p<0.001, ****p<0.0001.
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In assessing the density of DAPI+ cells along the scaffold periphery, peak cell densities
were noted in the seeded DAT scaffold group at 3 weeks relative to the unseeded
controls, as well as the other time points (Figure 4.16A). No significant changes in cell
density were observed in the unseeded implants over time. Further, analysis of the
numbers of EGFP+Iba1+DAPI+ cells revealed similar trends to the total DAPI+ cell
counts, with significantly greater numbers of EGFP+Iba1+DAPI+ cells within the seeded
scaffold group at 3 weeks relative to the unseeded controls and the other time points
examined (Figure 4.16B).
EGFP+Iba1-DAPI+ cells were also observed at low levels within the implants, suggesting
the presence of other myeloid cell populations such as neutrophils [316, 317].
Quantitative assessment of the numbers of EGFP+Iba1-DAPI+ cells demonstrated that
there were no differences between the seeded and unseeded scaffold groups at any of the
time points examined (Figure 4.16D). However, within the seeded group, the number of
EGFP+Iba1-DAPI+ cells appeared to gradually decrease over time, with a significant
difference observed between 1 and 8 weeks post-implantation. In the unseeded group, a
small but non-significant increase in the EGFP+Iba1-DAPI+ cell population was noted
between 1 and 3 weeks, followed by a significant decline at 5 and 8 weeks relative to the
3 week time point. Variable numbers of EGFP+Iba1-DAPI+ cells were observed at the 1
and 3 week time points suggesting that dynamic changes in this population may be
occurring at these time points.
In order to account for the differences in cell densities observed along the implant
periphery, the numbers of EGFP+Iba1+DAPI+ cells and EGFP+Iba1-DAPI+ cells were
normalized to the total number of DAPI+ cells counted within each region (Figure
4.16D). The relative fraction of EGFP+Iba1+DAPI+ cells was significantly increased at 3
weeks compared to the other time points in both the seeded and unseeded implants, with
the EGFP+Iba1+DAPI+ cells representing >60% of the total cell population. These data
suggest that the peak influx of EGFP+Iba1+DAPI+ cells occurred at 3 weeks within the
seeded and unseeded implants, with greater total cell recruitment in the ASC-seeded
group. The EGFP+Iba1+DAPI+ cell population then declined at 5 and 8 weeks. Analysis
of the relative fraction of total EGFP+DAPI+ cells (i.e. the pooled population of
75

EGFP+Iba1+DAPI+ and EGFP+Iba1-DAPI+ cells) showed a significant increase in this
population within the seeded and unseeded implants at 3 weeks relative to the other time
points, similar to that of the EGFP+Iba1+DAPI+ cell population.

4.5.2

Macrophage phenotypic markers in DAT scaffolds

To assess the potential for donor ASCs to modulate macrophage phenotype within DAT
scaffolds, myeloid cell expression of the macrophage phenotypic markers inducible nitric
oxide synthase (iNOS) and arginase-1 (Arg-1) were assessed within ASC-seeded and
unseeded implants at 1, 3, 5, and 8 weeks post-implantation. iNOS is considered an M1
macrophage marker and is associated with the metabolism of arginine, forming nitric
oxide (NO), which is used as a defense mechanism via oxidative/nitrosative damage
[318]. M2-polarized macrophages are associated with the expression of Arg-1, an
enzyme that indirectly limits arginine availability for NO production by hydrolyzing
arginine, forming ornithine and urea [318]. Thus, iNOS and Arg-1 expression were
examined in EGFP+ myeloid cells within the ASC-seeded and unseeded implants using
separate serial 5 µm sections to co-stain EGFP with iNOS, and EGFP with Arg-1.
Expression of iNOS and Arg-1 were observed within EGFP+ myeloid cells in both seeded
and unseeded implants at all time points examined (N=5-6 implants/treatment group/time
point; Figure 4.17 and 4.18, staining controls shown in Supplementary Figures 4 and 5;
single channels shown in Supplementary Figures 6-9). Qualitatively, there did not appear
to be major differences in the pattern of iNOS or Arg-1 expression within myeloid cells
when comparing the seeded and unseeded groups at the time points investigated.
Expression of iNOS by EGFP+ myeloid cells appeared to peak at 3 weeks relative to the
other time points, and partially declined thereafter (Figure 4.17). Qualitative assessment
of Arg-1 expression in myeloid cells within adjacent 5 µm sections showed low levels of
EGFP+Arg-1+DAPI+ cells present at all time points investigated, with no major
differences noted between time points (Figure 4.18).
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Figure 4.17. Myeloid cell expression patterns of iNOS appear similar between
seeded and unseeded DAT scaffolds. EGFP+ myeloid cells were observed to express
iNOS at all time points in both seeded (left panels) and unseeded (right panels) implants.
N=5-6 implants/scaffold group/time point. Dotted line: scaffold periphery. Blue: cell
nuclei, green: EGFP, red: iNOS. Arrows: EGFP+iNOS+DAPI+ cells. Scale: 50 µm.
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Figure 4.18. Myeloid cell expression patterns of Arg-1 appear similar between
seeded and unseeded DAT scaffolds. EGFP+ myeloid cells were observed to express
Arg-1 at all time points in both seeded (left panels) and unseeded (right panels) implants.
Dotted line: scaffold periphery. N=5-6 implants/scaffold group/time point. Blue: cell
nuclei, green: EGFP, red: Arg-1. Arrows: EGFP+Arg-1+DAPI+ cells. Scale: 50 µm.
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Chapter 5

5

Discussion

Adipose-derived stem/stromal cells (ASCs) represent a clinically-translational cell source
that can secrete beneficial paracrine factors with the capacity to promote tissue
regeneration [126, 127]. Previous work from the Flynn laboratory has demonstrated that
decellularized adipose tissue (DAT) scaffolds are a promising ASC delivery platform to
promote in vivo adipose tissue regeneration for applications in plastic and reconstructive
surgery [4]. However, a detailed understanding of the mechanisms of ASC-mediated
tissue regeneration and the role of extracellular matrix (ECM)-derived scaffolds are
critical for designing improved strategies that ensure stable and predictable regeneration.
In the present work, dual transgenic reporter mouse models were applied to track and
characterize syngeneic donor ASCs and infiltrating myeloid cell populations in tandem.
The results demonstrated that the donor ASCs were retained over the course of the 8week study and enhanced total cell recruitment and adipogenesis within the
subcutaneously-implanted DAT scaffolds.
The first phase of this study involved developing protocols to isolate, culture, and
characterize mouse ASCs, which had not been previously done in the Flynn laboratory.
In contrast to human ASCs, mouse ASCs are much less well-characterized. In addition,
methodological details for mouse ASC isolation and culture are often lacking in
published studies, including the specific fat depots that are used. For the present work,
initial emphasis was placed on isolating ASCs from the epididymal fat pad of the dsRed
mice, which is a large depot that was used as the cell source in previous studies in the
Wistar rat model [4, 182]. However, the mouse ASCs isolated from this depot did not
expand well in culture, and cell death frequently occurred between passage 2 and passage
4. In an attempt to improve cell expansion and survival, a number of variables were
explored, including different media formulations and flask coatings with Matrigel or
fibronectin, but these appeared to have little impact on long-term cell viability and
proliferation. Subsequently, the inguinal fat depot was explored as an alternative ASC
source. The inguinal ASCs could be expanded more readily in culture, particularly by
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using specially treated PrimariaTM flasks to promote cell attachment for initial plating of
the cells after isolation, as well as seeding flasks at relatively high cell densities (6,0007,000 cells/cm2) when passaging. As such, the inguinal depot was selected for ASC
isolations and was used in all experiments thereafter. Characterization of the inguinal
depot-derived ASCs showed that these cells expressed mesenchymal cell surface
markers, and could be induced to differentiate in culture along the adipogenic,
osteogenic, and chondrogenic lineages, concordant with previous observations [105, 106,
319-323]. Further, protocols were established for dynamic seeding of the DAT scaffolds
using ASCs sourced from the inguinal depot of the dsRed mice.
For the in vivo studies, DAT scaffolds seeded with dsRed+ ASCs were subcutaneously
implanted along with unseeded controls into syngeneic MacGreen mice. Histological
assessment of the implants revealed a thin layer of fibrous connective tissue surrounding
both the seeded and unseeded scaffolds. The fibrous layer may have formed due to an
initial foreign body response or potentially due to movement of the implant within the
subcutaneous space [324]. Qualitatively, the implant volume appeared to be relatively
consistent over time, with the exception of the seeded scaffold group at 8 weeks. At this
time point, the ASC-seeded scaffolds appeared to be slightly contracted, which may have
been associated with increased cell infiltration and remodelling observed by Masson’s
trichrome staining. However, given that the DAT is highly hydrated, deformable, and can
become remodeled and integrated with the surrounding tissues over time, long-term
volume retention is difficult to measure quantitatively. Potentially, body composition
analysis with cone beam volumetric µCT imaging could be applied in future work to
perform longitudinal tracking of the implant volume [325].
In assessing total cell recruitment, ASC-seeding was shown to increase host cell
infiltration into the DAT scaffolds relative to the low levels of infiltration observed in the
unseeded controls. The low degree of cell infiltration within the unseeded DAT is in
agreement with a previous study using a viscous DAT suspension prepared from human
lipoaspirates, which showed similar low levels of cell infiltration at 7 weeks after
subcutaneous injection in mice [175]. While both donor ASCs and myeloid cells were
investigated in the present study, other cell types that may be present within the implants
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include fibroblasts, pericytes, endothelial cells, host ASCs or MSCs, more committed
adipogenic progenitors, and other leukocyte populations. The increase in total cell
recruitment that was observed within the seeded scaffolds may be due to secretion of
chemotactic factors by the ASCs, such as chemokine (C-C motif) ligand (CCL)-2,3,4,7
and -12 associated with leukocyte recruitment [12, 13]. In addition, chemokine (C-X-C)
motif ligand 12 (CXCL-12), also termed stromal-derived factor-1, has been implicated as
a chemokine involved in MSC homing to sites of injury [326]. Moreover, work by
Stuermer et al. identified CXCL-12 as a key factor that induced ASC migration, with
antibody neutralization of the CXCL-12 receptors C-X-C chemokine receptor (CXCR)-4
and CXCR7 significantly inhibiting the ASC migratory capacity [327]. While these
studies suggest that leukocyte populations and MSCs may be recruited by ASCs to the
DAT, further experiments are required in order to elucidate the different cell types
present within the implants, and the mechanisms for recruitment.
ASC-seeding of ECM-derived scaffolds has been shown to enhance tissue regeneration
for a number of applications, including for repair of cartilage defects and damaged
myocardium, as well as for wound healing and adipose tissue regeneration [4, 276, 328330]. A previous study from the Flynn laboratory demonstrated that seeding the DAT
with allogeneic ASCs enhanced angiogenesis and adipogenesis within DAT scaffolds
implanted subcutaneously in immunocompetent Wistar rats [4]. In the present study,
while quantitative measurements showed that fat formation was also enhanced in the
ASC-seeded group using the syngeneic transgenic mouse model, on average, greater fat
formation was observed within the rat model at 8 weeks. These differences may be
related to species variability in terms of the host response to the DAT as well as ASC
function.
In order to investigate donor dsRed+ ASC retention, immunohistochemical staining was
performed to probe for dsRed within the implants. The staining results showed that the
syngeneic ASCs appeared to be retained over the course of the 8 week study. Variable
levels of dsRed staining were observed within the seeded implants, which may be due to
donor ASC migration or cell death, or possible regional variations in ASC localization.
Nonetheless, significant differences in the percentage area of dsRed staining were
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observed in the seeded versus unseeded scaffolds at 8 weeks post-implantation, with the
levels suggesting that the donor cells were retained within the implants over the duration
of the study. Relatively few studies to date have quantitatively examined cell retention
within decellularized scaffolds over time; however, these studies are important to both
assess the efficacy of the delivery platform and the mechanisms of regeneration. The
findings of the present work are consistent with a study by Sharma et al. who
demonstrated the retention of autologous bone marrow-derived MSCs (bmMSCs) over 10
weeks within decellularized small intestinal submucosa (SIS) scaffolds in a baboon
bladder regeneration model [202]. Overall, these results are promising, particularly given
that poor retention of donor MSCs delivered in suspension has been identified as a key
hurdle limiting the therapeutic efficacy of these cells [200, 201].
Immunohistochemical analysis of the dsRed+ donor ASCs also revealed that newly
formed adipocytes within the implants did not stain positive for dsRed, suggesting that
these tissues were host-derived. In the previous study from our laboratory using the
subcutaneous rat model, allogeneic donor ASCs were also shown to support fat formation
through indirect mechanisms, as the donor cells qualitatively declined within the seeded
implants at 4 and 8 weeks, becoming undetectable at 12 weeks [4]. Since syngeneic
ASCs were used in the present work, the accelerated decline in the donor ASC population
within the rat study may be related to a host response to the allogeneic cells. Work from
other groups has also supported the indirect mechanisms of donor ASCs, since the
subcutaneous delivery of human adipose-derived cell populations within ECM-derived
hydrogels enhanced host-derived adipogenesis in immune-compromised mouse models
[189, 331]. More specifically, staining for human-specific markers revealed that the
human cells did not co-localize with newly formed adipocytes in these studies [189, 331].
Collectively, these results suggest that paracrine factor secretion may be a predominant
mechanism through which ASCs promote adipogenesis within a tissue-engineering
context.
As an additional method for donor cell tracking, in vivo optical imaging was performed to
measure the levels of dsRed fluorescence within the implant regions over time, based on
promising preliminary findings with in vitro cultured ASC-seeded DAT scaffolds. The in
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vivo experiments revealed differences in fluorescence between the seeded and unseeded
scaffolds at 24 h, 72 h, 3, and 5 weeks post-implantation, but not at the 1 and 8 week time
points. The failure of the optical imaging strategy to corroborate the
immunohistochemical results may be related to changes in the hair growth cycle,
resulting in darkening of the mouse skin pigment observed at some of the time points.
Indeed, the optimal window for fluorescent detection using in vivo optical systems is
between approximately 600 nm and 900 nm [332]. At wavelengths below 600 nm, light
scattering and absorption by endogenous chromophores (such as melanin and
haemoglobin) can impede signal acquisition [332]. The peak excitation and emission
wavelengths for dsRed are 557 nm and 592 nm respectively, and thus do not fall within
the range of the optimal window. As such, changes in skin colouring or hair growth may
have negatively impacted signal acquisition. Moreover, at 8 weeks post-implantation, the
seeded implants appeared partially contracted, and the donor dsRed+ ASCs had migrated
farther into the interior of the implant, which may have also contributed to the reduced
signal at this time point. In future studies, bioluminescence imaging could be explored
using ASCs genetically engineered to express luciferase, as this would likely give a more
robust signal relative to fluorescent proteins [332].
In order to investigate the infiltration of myeloid cells into the DAT scaffolds, initial
experiments focused on staining for enhanced green fluorescent protein (EGFP),
expressed by myeloid cells in the MacGreen mouse model [25, 26], along with costaining for Iba1, a marker expressed by monocytes and macrophages [314, 315]. ASCseeding of the DAT was found to partially influence the infiltration of Iba1+ myeloid cells
as a significantly greater number of EGFP+Iba1+ cells were detected along the implant
periphery within the seeded versus unseeded implants at 3 weeks post-implantation. This
suggests that the donor ASCs may have secreted chemotactic factors that increased
myeloid cell infiltration. In support of this, Chen et al. demonstrated that the conditioned
medium obtained from mouse bmMSCs cultured under hypoxic conditions significantly
enhanced the in vitro migration of peripheral blood-derived CD14+ human monocytes
[333]. Additionally, the bmMSC medium contained high levels of CCL-3 and CCL-4,
and subcutaneous injection of the conditioned media in a mouse excisional wound model
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selectively increased infiltration of F4/80+ macrophages, but not Gr1+ (granulocyte
marker) or CD3+ (T cell marker) cells within the wounds relative to control medium or
conditioned media obtained from fibroblast culture [333]. Macrophage recruitment by
ASCs is an emerging area of interest, and the in vivo studies to date have focused
primarily on assessing the effects of ASCs and MSCs on macrophage phenotype, rather
than recruitment. In the previous study from our laboratory using the subcutaneous rat
model, quantitative assessment of CD68+ macrophages showed similar levels between
ASC-seeded and unseeded DAT scaffolds and macrophage numbers remained relatively
consistent between 1 and 12 weeks post-implantation, albeit changes in phenotype were
noted [4]. In the current mouse study, the altered macrophage infiltration kinetics
observed between time points and implant groups may also be related to species
differences in terms of ASC function and the host response to the DAT. Importantly, the
quantitative cell counting performed here was completed using 20X images taken along
the implant periphery in order to control for the variable degrees of cell infiltration
toward the interior of the implant. While further analysis could be performed on regions
closer to the interior, in the majority of the implants, there was minimal or no cell
infiltration beyond the border of the regions analyzed.
Analysis of the fraction of EGFP+Iba1+ cells relative to the total cells counted along the
implant periphery demonstrated a peak in this cell population within both the seeded and
unseeded implants at 3 weeks. At this time point, EGFP+Iba1+ cells represented >60% of
the total nucleated cell population compared to approximately 10-20% at the 1, 5, and 8
week time points. Moreover, co-staining for EGFP with the M1 macrophage marker
inducible nitric oxide synthase (iNOS) showed that qualitatively, the majority of
infiltrating macrophages at 3 weeks were pro-inflammatory M1-like cells. Together these
data suggest that the peak inflammatory response occurred at 3 weeks and had partially
resolved by 5 and 8 weeks post-implantation, as the levels of macrophages declined
within the implant region. Indeed, clearance of macrophages is crucial for the resolution
of acute inflammation [334]; however, the mechanisms responsible for macrophage
clearance are not clear. Some reports have suggested that macrophage efflux into
neighbouring lymph nodes is a predominant mechanism by which macrophages decline
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within a tissue [335, 336], while others have shown that local apoptosis may be the
primary mechanism of clearance in the lung and peritoneum [337, 338]. As such,
investigation into the apparent decline in the macrophage population between 3 and 5
weeks may present an interesting avenue of investigation for future studies.
The EGFP and Iba1 co-staining results also identified a small population of EGFP+Iba1cells within the implants. Moreover, ASC-seeding appeared to accelerate the decline in
this cell population relative to the unseeded controls. Given that EGFP expression is
controlled by the macrophage colony-stimulating factor 1 receptor (Csf1r) promoter in
the MacGreen model [26], the EGFP+Iba1- cells could represent a heterogeneous cell
population. Notably, neutrophils express EGFP in the MacGreen model [25], and likely
represent a fraction of the EGFP+Iba1- population as neutrophils do not express the Iba1
marker [316, 317]. In humans, neutrophils are typically cleared from injured or infected
tissues within 3-5 days of the initial insult [261]. However, in mouse models, these cells
can persist for longer periods of time [339]. For example, in mouse models of spinal cord
injury, neutrophils are observed to persist at the injured site and a second peak of
neutrophil infiltration can occur several weeks after injury during the process of tissue
repair [340, 341]. Other cell types that may contribute to the EGFP+Iba1- cell population
may include dendritic cells [26] and myeloid-derived suppressor cells [25], each of which
have been shown to express low levels of EGFP within the MacGreen model [25, 26] and
are involved in regulating the T cell response. Ultimately, further characterization studies
would be required in order to elucidate the different myeloid cell types that may be
involved and their potential roles in implant remodeling.
Finally, staining for EGFP in conjunction with either the M1 macrophage marker iNOS,
or the M2 marker arginase-1 (Arg-1) was performed in adjacent tissue sections to
examine macrophage phenotypes within the ASC-seeded and unseeded DAT implants.
iNOS and Arg-1 staining were observed within EGFP+ myeloid cells at all time points
examined, and qualitatively, the expression patterns appeared similar between the seeded
and unseeded groups. More specifically, a larger proportion of EGFP+iNOS+ cells was
observed, with low levels of EGFP+Arg-1+ cells at all time points. The process of tissue
repair and regeneration is associated with a shift from pro-inflammatory M1-polarized
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macrophages to predominantly M2-polarized macrophages involved in regulating
inflammation and tissue remodeling [342]. Moreover, ASCs have been shown to aid in
this process by promoting an M2 macrophage phenotype [9, 11, 135]. Thus, the finding
that EGFP+iNOS+ cells appeared in greater numbers than EGFP+Arg-1+ cells requires
further study, particularly given that the robust infiltration of EGFP+Iba1+ cells at 3
weeks appeared to diminish at 5 and 8 weeks post-implantation, suggesting that the proinflammatory response had partially resolved. Potentially, investigation into time points
between 3 and 5 weeks would reveal an increase in M2-like macrophages that may have
played a role in dampening the inflammatory response observed at the 3 week time point.
Alternatively, M2-polarized macrophages may predominate at time points beyond 8
weeks post-implantation, as was found in the previous rat study from our laboratory [4].
These additional experiments would also help to determine whether ASCs influenced
macrophage phenotype within the seeded implants.
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Chapter 6

6

Conclusions and Future Directions

6.1 Summary of findings
In the first objective, methods were established to isolate adipose-derived stem/stromal
cells (ASCs) from the inguinal fat pads of dsRed mice, and cell surface markers were
characterized along with assessment of multilineage differentiation capacity. Flow
cytometry results revealed that the ASCs expressed high levels of the stromal cell
markers CD29, CD44, and CD90 as expected. In addition, the lack of positive staining
for CD31 and CD45 precluded contamination by endothelial cells and leukocytes,
respectively. Further, the mouse ASCs were shown to differentiate along the adipogenic,
osteogenic, and chondrogenic lineages. Culture of ASCs in adipogenic differentiation
media for 14 days showed increased intracellular lipid accumulation characteristic of
developing adipocytes, as assessed through oil red O staining, relative to non-induced
controls maintained in proliferation medium. The induced adipogenic cultures also
displayed significantly increased activity of the lipogenic enzyme glycerol 3-phosphate
dehydrogenase (GPDH) compared to controls. In terms of osteogenic differentiation,
significantly increased activity of the enzyme alkaline phosphatase (ALP), an early
marker of osteogenesis, was observed after 7 days of culture in osteogenic medium
relative to non-induced controls. Moreover, small mineral deposits could be detected in
the induced osteogenic cultures but not controls after 28 days of culture. Chondrogenic
differentiation was performed by culturing the ASCs in 3D cell aggregates, and induced
aggregate cultures were shown to express a qualitatively higher ratio of collagen II to
collagen I relative to non-induced controls, indicative of chondrogenic differentiation.
Finally, a pilot study was performed in order to verify the attachment of mouse ASCs to
decellularized adipose tissue (DAT) scaffolds under dynamic seeding conditions.
Qualitative visualization of ASC attachment at three different seeding densities (0.5x106
ASCs/scaffold, 1x106 ASCs/scaffold, and 2x106 ASCs/scaffold) showed greater levels of
attachment at higher seeding densities. A seeding density of 2x106 ASCs/scaffold was
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selected for subsequent in vivo studies since this density provided a more homogenous
ASC distribution along the scaffold periphery.
After initial characterization of the dsRed+ mouse ASCs, experiments focused on
assessing the in vivo response to ASC-seeded DAT scaffolds and unseeded controls
implanted in syngeneic MacGreen mice at 72 h, 1, 3, 5, and 8 weeks post-implantation.
For the second objective, Masson’s trichrome staining was performed to assess total cell
infiltration and tissue remodeling within the implants. Quantitative measurements of total
cell recruitment revealed a significant increase in the fraction of the implant infiltrated by
cells within the ASC-seeded versus unseeded implants at 8 weeks post-implantation. In
addition, quantitative analysis of adipose tissue remodeling showed that adipocytes were
present in a greater number of ASC-seeded implants at 1, 3, 5, and 8 weeks postimplantation relative to unseeded controls. The seeded implants also showed a greater
percentage of adipose tissue remodeling at 3, 5, and 8 weeks compared to the unseeded
group.
The third objective focused on assessing dsRed+ donor cell retention in the DAT implants
over time using immunohistochemistry and in vivo optical imaging.
Immunohistochemical staining at the 72 h, 1, 3, 5, and 8 week time points showed
positive staining for dsRed in the seeded implants at all time points, with no positive
staining in the unseeded controls. Quantitative measurements of the percentage of
positively stained area confirmed that the syngeneic donor ASCs were retained in the
majority of seeded implants over the course of the 8 week study. Using an optical
imaging strategy to measure levels of dsRed fluorescence, an in vitro pilot study showed
that differences in dsRed fluorescence could be observed in scaffolds seeded with varying
densities of ASCs. However, when this strategy was applied in vivo to assess the levels of
dsRed fluorescence within seeded and unseeded implant regions, the data only partially
corroborated the immunohistochemical findings. More specifically, significant
differences in the levels of dsRed fluorescence were obtained in comparing the ASCseeded and unseeded implant regions at 24 h, 72 h, 3, and 5 weeks post-implantation, but
a significant decline in fluorescence was observed at the 1 and 8 week time points. This
inconsistency was likely due to darkening of the mouse skin that influenced light
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scattering and absorption at 1 week, along with potential changes in the implant
morphology at 8 weeks that may have impeded signal acquisition.
The final objective was to investigate the infiltrating enhanced green fluorescent protein
(EGFP+) myeloid cell population within the ASC-seeded and unseeded DAT scaffolds at
1, 3, 5, and 8 weeks post-implantation in the MacGreen mouse model.
Immunohistochemical co-staining for EGFP and the monocyte/macrophage marker Iba1
suggested that macrophage infiltration peaked along the implant periphery within both
the seeded and unseeded scaffolds at 3 weeks post-implantation. This population
subsequently declined at the 5 and 8 week time points. Macrophage recruitment appeared
to be augmented within the ASC-seeded implants relative to the unseeded controls at 3
weeks, as significantly greater numbers of EGFP+Iba1+ cells were noted in the seeded
group at this time point. Qualitative assessment of the pro-inflammatory M1 macrophage
marker inducible nitric oxide synthase (iNOS) appeared to show relatively high levels of
expression within EGFP+ myeloid cells in both scaffold groups at each of the time points
examined. Relative to iNOS, the M2 macrophage marker arginase-1 (Arg-1) was less
frequently observed within the seeded and unseeded implants at each time point. There
did not appear to be major differences in the levels of iNOS and Arg-1 expression when
qualitatively comparing the ASC-seeded and unseeded implants.

6.2 Conclusions
Overall, these findings support the combined use of DAT and ASCs for adipose tissue
engineering applications. Robust protocols were established to isolate and culture the
mouse ASCs from the inguinal adipose tissue depot. A detailed characterization of the
ASCs provided a more in-depth understanding of the cell population used to stimulate
regeneration within the DAT scaffolds. ASC-seeding of the DAT scaffolds was shown to
augment total cell recruitment and adipogenesis within the implants without contributing
directly to the newly formed adipocytes. In addition, the syngeneic donor ASCs were
retained within the DAT scaffolds over the course of the 8 week study, further supporting
the use of DAT scaffolds as a cell delivery vehicle. The characterization of infiltrating
myeloid cell populations requires further study, but suggests that donor ASCs may have
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influenced myeloid cell infiltration kinetics. Taken together, these findings provide
additional evidence supporting the use of DAT scaffolds for adipose tissue regeneration.
The use of the dsRed and MacGreen transgenic mouse models facilitated tracking of the
donor ASCs and infiltrating myeloid cells, and aids with investigation into regenerative
mechanisms.

6.3 Future recommendations
In future work, the Masson’s trichrome and immunohistochemical staining should be
repeated using multiple sections throughout the implants in order to account for potential
regional variations in tissue remodeling, total cell recruitment, ASC retention, and
macrophage recruitment. In addition, it would be interesting to investigate other cell
types that infiltrate the DAT scaffolds, such as adipogenic progenitors, which could be
identified through co-staining for CD34+CD29+CD24+ cells [343]. Angiogenesis could
also be further explored by performing blood vessel counts within the Masson’s
trichrome stained sections, or by staining for markers such as CD31 and vascular
endothelial growth factor (VEGF).
In assessing the host response to the ASC-seeded and unseeded DAT scaffolds, future
work should focus on identifying other populations of immune cells that may be present
within the DAT. In particular, experiments should be performed to examine the
EGFP+Iba1- cells to identify more specifically the myeloid cell types within this
population. More specifically, immunohistochemical staining for neutrophils markers
(such as Ly6G or neutrophil elastase) could be performed with EGFP co-staining. As T
cells have also been shown to mediate remodeling of extracellular matrix (ECM)-derived
scaffolds [277], staining for innate γδ T cells and adaptive CD3+CD4+ T helper cells and
CD3+CD8+ cytotoxic T cells could be performed, along with co-staining for
CD4+CD25+FOXP3+ for regulatory T cells [344]. These additional experiments would
aid in furthering the understanding of the potential immunomodulatory role of the donor
ASCs. To supplement immunohistochemical staining experiments, western blotting could
be performed to assess protein levels of pro- and anti-inflammatory cytokines, such as
tumour necrosis factor-alpha (TNFα) and interleukin (IL)-10, within the ASC-seeded and
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unseeded implants. In addition, flow cytometry could be performed in future work using
collagenase-digested implants in order to more quantitatively assess the abundance of
different cell types that may be present within the scaffolds. Alternatively, laser capture
microdissection could be applied in order to extract dsRed+ donor ASCs and EGFP+
myeloid cells from the implants for further characterization with reverse transcription
quantitative PCR [345].
Given that significant differences were observed between the ASC-seeded and unseeded
implants in terms of total cell recruitment, as well as macrophage recruitment, further
immunohistochemical staining could be performed to examine the expression of
chemotactic factors. This could be done by staining for dsRed to identify the donor
ASCs, along with co-staining for chemotactic factors such as chemokine C-X-C motif
ligand 12 (CXCL-12), which has been implicated in the recruitment of leukocyte and
MSC populations [12, 13, 326].
With respect to studies that could be performed in the long-term, methods to further
enhance fat formation within the DAT scaffolds should be explored using the mouse
models applied in this study. This may allow for more apparent differences between the
seeded and unseeded implants in terms of adipose tissue remodeling and the host
response. For example, DAT scaffolds could be implanted into the inguinal region of the
mouse since the scaffold would be adjacent to the femoral and epigastric arteries, which
may allow for enhanced recruitment of progenitor cell populations and immune cells.
Further, this is also the location from which the donor ASCs are obtained, and this may
influence recruitment of progenitors and other cell types from neighbouring tissues since
the donor ASCs would be in close proximity to their native fat depot. Alternatively, Kelly
et al. have developed an in vivo model for engineered adipogenesis by using the
superficial epigastric artery as a vascular pedicle within a silicone-encased Matrigel
chamber [346]. A similar technique could be applied by surgically implanting the DAT
scaffolds to encircle the epigastric artery.
Besides investigating alternative implantation sites, strategies could be explored to alter
donor ASC function as a potential means to augment adipose tissue regeneration. For
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example, ASC-seeded DAT scaffolds could be cultured in adipogenic differentiation
medium to pre-differentiate the syngeneic ASCs prior to implantation. This technique
was explored in a study by Cho et al., in which human ASC-seeded fibrin scaffolds were
implanted subcutaneously into athymic mice, showing enhanced adipogenesis in the predifferentiated versus undifferentiated groups [347]. Alternatively, ASC-seeded DAT
scaffolds could be cultured under hypoxic conditions prior to implantation. While
hypoxic exposure has been shown to inhibit adipogenic differentiation of ASCs [348],
there are studies to suggest that hypoxia can enhance the secretion of angiogenic and
immunomodulatory factors [349, 350]. Since the current study suggests that the donor
ASCs did not contribute directly to newly formed adipocytes, augmented paracrine factor
secretion through hypoxic pre-conditioning could be an interesting avenue of exploration.
Additional strategies to enhance fat formation could include the addition of growth
factors to the DAT prior to implantation. In particular, incorporating basic fibroblast
growth factor (bFGF) into collagen [351, 352] or gelatin-based [353] scaffolds has been
shown to augment adipogenesis after subcutaneous implantation in mice. bFGF is a
potent mitogen and chemoattractant, and has been shown to promote angiogenesis and
adipogenesis in vivo [352, 354]. Co-delivery of bFGF and ASCs within the DAT may
have an additive effect in promoting adipogenesis, as was reported using bFGF-loaded
fibrin scaffolds pre-seeded with ASCs and implanted subcutaneously into mice [347]. As
an alternative approach, mouse ASCs could be genetically engineered to overexpress
bFGF prior to delivery. Genetically engineered ASCs could allow for more stable growth
factor delivery over time given that the syngeneic ASCs appeared to be well-retained
within the DAT over the course of the present study.
In addition to investigating methods to enhance fat formation, a cell type control could be
included as an additional experimental group in order to further elucidate the effects of
the donor ASCs relative to another cell type. For example, the DAT scaffolds could be
seeded with syngeneic dermal fibroblasts, since these cells function primarily to secrete
ECM, and are much more limited in terms of their ability to secrete immunomodulatory
and angiogenic factors [355, 356]. Alternatively, a comparison study could be performed
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in order to assess the effects of MSCs isolated from different tissue sources (such as
adipose, bone marrow, and cord blood) on tissue regeneration within the DAT implants.
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Appendix 1

Supplementary Figure 1. Representative scatter plots depicting fluorescence minus
one (FMO) flow cytometry controls. A) dsRed FMO demonstrating gating of wild-type
ASCs positively stained with an APC-conjugated antibody. B) Viability dye FMO
showing gating of APC-stained dsRed+ ASCs not stained with viability dye. C) APC
FMO demonstrating gating of viability dye-stained dsRed+ ASCs without antibody
staining.

123

Supplementary Figure 2. Immunohistochemistry of tissue-positive (left panels) and
no primary (right panels) controls for collagen I (top panels) and collagen II
(bottom panels). Porcine auricular cartilage samples with surrounding skin showed
positive expression of collagen I in the skin and collagen II expression within the
cartilage. Green: positive staining for collagen I or collagen II (as indicated), blue: cell
nuclei. Scale: 200 µm.

124

Supplementary Figure 3. Immunohistochemistry of tissue-positive, no primary, and
tissue-negative controls for dsRed staining. Representative images of the scaffold
periphery in dsRed-stained tissue sections of DAT scaffolds implanted in dsRed mice
(tissue-positive control; top panel), or in MacGreen mice with no dsRed+ ASCs
administered (tissue-negative control; bottom panel). A representative no primary control
is also shown (middle panel). Brown: positive staining for dsRed. Scale: 200 µm.
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Supplementary Figure 4. Immunohistochemistry of mouse spleen tissue-positive, no
primary, and tissue-negative controls for EGFP staining. Representative images of
EGFP-stained mouse spleens from MacGreen mice (tissue-positive control; left panel),
and wild-type mice (tissue-negative control; right panel). A representative no primary
control is also shown (middle panel). Green: positive staining, blue: cell nuclei. Scale:
100 µm.
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Supplementary Figure 5. Immunohistochemistry of mouse spleen tissue-positive
(left panels) and no primary (right panels) controls for Iba1 (top panels), iNOS
(middle panels), and Arg-1 (bottom panels). Yellow (for Iba1) or green (for iNOS and
Arg-1): positive staining, blue: cell nuclei. Scale: 100 µm.
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Supplementary Figure 6. Single channel and merged images of ASC-seeded DAT
scaffolds co-stained for EGFP and iNOS. Arrows: EGFP+iNOS+DAPI+ cells. Dotted
line: scaffold periphery. Green: EGFP, red: iNOS, blue: cell nuclei. Scale: 50 µm.
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Supplementary Figure 7. Single channel and merged images of unseeded DAT
scaffolds co-stained for EGFP and iNOS. Arrows: EGFP+iNOS+DAPI+ cells. Dotted
line: scaffold periphery. Green: EGFP, red: iNOS, blue: cell nuclei. Scale: 50 µm.
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Supplementary Figure 8. Single channel and merged images of ASC-seeded DAT
scaffolds co-stained for EGFP and Arg-1. Arrows: EGFP+Arg1+DAPI+ cells. Dotted
line: scaffold periphery. Green: EGFP, red: Arg-1, blue: cell nuclei. Scale: 50 µm.
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Supplementary Figure 9. Single channel and merged images of unseeded DAT
scaffolds co-stained for EGFP and Arg-1. Arrows: EGFP+Arg1+DAPI+ cells. Dotted
line: scaffold periphery. Green: EGFP, red: Arg-1, blue: cell nuclei. Scale: 50 µm.
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